The accompanying interim consolidated financial
statements of The Greenrose Holding Company Inc. (the “Company”) should be read in conjunction with the 10-K that was filed
with the United States Securities and Exchange Commission (the “SEC”). The accompanying consolidated financial statements
have been prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”) for
interim financial information and in accordance with the instructions to Form 10-Q and Article 8 of Regulation S-X. Accordingly, since
they are interim statements, the accompanying consolidated financial statements do not include all the information and notes required
by GAAP for complete financial statement presentation. In the opinion of management, the interim consolidated financial statements reflect
all adjustments (consisting of normal, recurring adjustments) that are necessary for a fair presentation of the financial position, results
of operations, and cash flows for the interim periods presented. Interim results are not necessarily indicative of results for a full
year.
In the opinion of management, the consolidated
financial statements contain all material adjustments, consisting only of normal adjustments considered necessary to present fairly the
financial condition, results of operations, and cash flows of the Company for the interim periods presented.
Notes to Condensed Consolidated Financial Statements
(Unaudited)
1. Nature of Operations and Summary of Significant Accounting Policies
The Company was originally incorporated in Delaware
on August 26, 2019 under the name Greenrose Acquisition Corp., as a special purpose acquisition company formed for the purpose of entering
into a merger, share exchange, asset acquisition, stock purchase, recapitalization, reorganization or similar business combination with
one or more businesses or entities as completed on the Closing Date.
On November 24, 2021, the Company changed the
name to The Greenrose Holding Company Inc. (“Greenrose”, the “Company”, or “Successor”) and on November
26, 2021 (the “Closing Date”), the Company consummated its business combination (the “Theraplant Merger” or “Theraplant
Business Combination”) with Theraplant, LLC, a Connecticut limited liability company (“Theraplant” or “Predecessor”),
a private operating company. The Theraplant Business Combination was consummated pursuant to the Agreement and Plan of Merger dated March
12, 2021 (as amended pursuant to that certain Amendment No. 1, dated as of August 10, 2021, to the Agreement and Plan of Merger (“Amendment
No. 1”), and that certain Amendment No. 2, dated as of November 26, 2021, to the Agreement and Plan of Merger (“Amendment
No. 2”), collectively, the “Theraplant Merger Agreement”), pursuant to which GNRS CT Merger Sub, a Connecticut limited
liability company and a wholly-owned subsidiary of Greenrose (“TPT Merger Sub”) was merged with and into Theraplant, with
Theraplant surviving the Merger as a wholly owned subsidiary of Greenrose. The financial results described herein for the dates and periods
prior to the Theraplant Business Combination relate to the operations of the Predecessor prior to the consummation of the Theraplant Business
Combination. The Consolidated Financial Statements after the Closing Date include the accounts of the Company and its wholly owned subsidiaries
including Theraplant.
On December 31, 2021, the Company and True Harvest
Holdings, Inc., a Delaware corporation and a wholly-owned subsidiary of the Company (“TH Buyer”), and True Harvest, LLC, an
Arizona limited liability company (“True Harvest”), consummated the acquisition of substantially all of True Harvest’s
assets and the assumption of certain of True Harvest’s liabilities (the “True Harvest Acquisition”), pursuant to that
certain Asset Purchase Agreement dated March 12, 2021, as amended by that Amendment No. 1 to the Asset Purchase Agreement dated July 2,
2021, that certain Amendment No. 2 to the Asset Purchase Agreement dated October 28, 2021, and that certain Amendment No. 3 to the Asset
Purchase Agreement dated December 31, 2021 (as it may be amended from time to time, the “Asset Purchase Agreement”).
The Company, through its wholly owned subsidiaries
(Theraplant and True Harvest) is a multi-state grower and producer of cannabis products dedicated to providing patients options to improve
their wellbeing. Theraplant is a Connecticut State licensed marijuana producer that hand selects premium cannabis genetics grown in a
controlled, clean environment, under the watch of an award-winning cultivation team, and tested by a third-party laboratory for pesticides
and microbiologics. True Harvest cultivates, manufactures, and sells medical marijuana in the State of Arizona, under a cultivation agreement
with a third-party licensor, and holder of a medical marijuana dispensary registration certificate from Arizona Department of Health Services
and is authorized to operate an off-site cultivation facility.
Following the transactions stated above, the Company
has authorized 150,000,000 shares of common stock with a par value of $0.001 per share, and 1,000,000 shares of Preferred stock with
a par value of $0.0001 per share. See Note 13 for additional details.
COVID-19
In March 2020, the World Health Organization declared
the coronavirus (COVID-19) a global pandemic. The COVID-19 outbreak and the response of governmental authorities to try to limit it are
having a significant impact on the private sector and individuals, including unprecedented business, employment and economic disruptions.
Management has been closely monitoring the impact of COVID-19, with a focus on the health and safety of the Company’s employees,
business continuity and supporting the communities where the Company operates. The Company has implemented various measures to reduce
the spread of the virus, including implementing social distancing measures at its cultivation facilities, manufacturing facilities, and
dispensaries, enhancing cleaning protocols at such facilities and dispensaries and encouraging employees to adhere to preventative measures
recommended by local, state, and federal health officials.
It is not possible for the Company to predict
the duration or magnitude of the adverse results of the outbreak and its effects on its business or results of operations at this time.
Liquidity and Going Concern
The Company’s primary sources of liquidity
are cash from operations, cash and cash equivalents on hand and private financing. The Company’s primary requirements for liquidity
are to fund its working capital needs, debt service, operating lease obligations, capital expenditures and general corporate needs. Theraplant
and True Harvest are generating cash from sales. Theraplant is deploying its capital reserves to acquire and develop assets capable of
producing additional revenues and earnings over both the immediate and near term to support its business growth and expansion.
As of September 30, 2022, we maintained a cash
and cash equivalents balance of $962 thousand and $4 thousand of restricted cash, with $135,638 thousand working capital deficit, and
we did not have adequate working capital resources to satisfy our current liabilities. As a result, after taking into account the Company’s
cash flow projections, we do not believe the Company will have sufficient cash on hand or available liquidity to meet its obligations
in the upcoming reporting periods, and we have substantial doubt regarding our ability to continue as a going concern.
We will need substantial additional capital to
fund our operations in future reporting periods. The Company expects cash flows to increase over time, but not sufficiently in the short
term to be able to pay for expenses, without raising additional capital. If we are unable to generate additional revenue and obtain financing on acceptable terms, or at
all, we will likely be required to cease our operations, pursue a plan to sell our operating assets, or otherwise modify our business
strategy, which could materially harm our future business prospects.
As of September 30, 2022, as a result of the substantial
doubt about our ability to generate sufficient working capital to satisfy our liabilities and continue as a going concern, the Company
has violated the terms of the agreement between the Company, DXR Finance LLC, as Agent, and lenders DXR-GL Holdings I, LLC, DXR-GL Holdings
II, LLC, and DXR-GL Holdings III, LLC (collectively, the “Lenders”) to the Credit Agreement dated November 26, 2021 (the “Credit
Agreement”) and the Loan Documents under the Credit Agreement. Pursuant to the terms of the Credit Agreement, the Company is required
to comply with quantitative ratios including adjusted EBITDA, net leverage ratio and secured net leverage ratios. As of September 30,
2022, the Company has not been in compliance with the financial covenants of the Credit Agreement with respect to the Term Loan (as defined
in the Credit Agreement). For these reasons, on October 2, 2022, the Agent for the Lenders under the Credit Agreement gave the Company
a Notice of Default and on October 10, 2022 a notice of additional default (collectively, the “Notice of Default”) without
invoking acceleration of indebtedness. Upon receipt of the Notice of Default and the occurrence of the corresponding cross defaults, we
are required to classify our long-term obligations as current liabilities. Upon the occurrence of such an event of default, if not timely
cured, all amounts outstanding under our Credit Agreement could be declared immediately due and payable, which is how our financial statements
are presented. If indebtedness under our Credit Agreement is accelerated, there can be no assurance that we will have sufficient assets
to repay the indebtedness. The Company has not cured any defaults under the Credit Agreement. But the Company is actively working with
the Agent and the Lenders to address the defaults; however, no assurances can be given as to the success of these actions. As reflected
in more detail in Note 8, all debt with covenant violations and cross default clauses have been classified as current given the event
of default. The only debt not considered current is the Imperial debt not due within the next twelve months which does not have a cross
default clause.
In addition to the obligations under the Credit
Agreement, the Company has certain debt obligations to sellers, our lender, and vendors which will require cash to meet their requirements.
The Company’s ability to continue meeting these contractual obligations will be reliant upon its ability to secure significant additional
capital funding or revise the contracts.
On November 10, 2022, the Company entered into
Amendment No. 2 to the Credit Agreement with the Credit Agreement Consenting Lenders and DXR Finance, LLC, as Agent pursuant to which
the Credit Agreement Consenting Lenders agreed to fund an additional $10,000 thousand of loans to, among other things, allow the Company to
continue to operate in the ordinary course and make the necessary payments to the Connecticut state regulator for conversion of Theraplant’s
license to adult-use recreational, with $5,000 thousand to be borrowed immediately on the effective date of the Amendment No. 2 to the Credit
Agreement and $5,000 thousand to be borrowed in one or more draws thereafter on or before December 31, 2022. The foregoing description of Amendment
No. 2 to the Credit Agreement is not complete and is qualified in its entirety by reference to the complete text of the Amendment No.
2 to the Credit Agreement, a copy of which is filed on November 14, 2022 as Exhibit 10.2 to the Current Report on Form 8-K and is incorporated
herein by reference.
Emerging Growth Company
The Company is an “emerging growth company,”
as defined in Section 2(a) of the Securities Act, as modified by the Jumpstart Our Business Startups Act of 2012 (the “JOBS Act”),
and it may take advantage of certain exemptions from various reporting requirements that are applicable to other public companies that
are not emerging growth companies including, but not limited to, not being required to comply with the independent registered public accounting
firm attestation requirements of Section 404 of the Sarbanes-Oxley Act, reduced disclosure obligations regarding executive compensation
in its periodic reports and proxy statements, and exemptions from the requirements of holding a nonbinding advisory vote on executive
compensation and stockholder approval of any golden parachute payments not previously approved.
Further, Section 102(b)(l) of the JOBS Act exempts
emerging growth companies from being required to comply with new or revised financial accounting standards until private companies (that
is, those that have not had a Securities Act registration statement declared effective or do not have a class of securities registered
under the Exchange Act) are required to comply with the new or revised financial accounting standards. The JOBS Act provides that a company
can elect to opt out of the extended transition period and comply with the requirements that apply to non-emerging growth companies but
any such election to opt out is irrevocable. The Company has elected not to opt out of such extended transition period, which means that
when a standard is issued or revised and it has different application dates for public or private companies, the Company, as an emerging
growth company, can adopt the new or revised standard at the time private companies adopt the new or revised standard. This may make comparison
of the Company’s financial statements with another public company which is neither an emerging growth company nor an emerging growth
company which has opted out of using the extended transition period difficult or impossible because of the potential differences in accounting
standards used.
Basis of Presentation
The accompanying condensed consolidated financial
statements have been prepared in accordance with generally accepted accounting principles in the United States of America (“GAAP”)
for interim financial information, and (ii) the instructions to Form 10-Q and Article 10 of Regulation S-X. In the opinion of our management,
our unaudited consolidated financial statements and accompanying notes (the “Consolidated Financial Statements”) include all
normal recurring adjustments that are necessary for the fair statement of the interim periods presented. Interim results of operations
are not necessarily indicative of results for the full year, or any other period. The Financial Statements should be read in conjunction
with our audited consolidated financial statements (and notes thereto) in our Annual Report on Form 10-K for the year ended December 31,
2021 (the “Annual Report”), as filed with the United States Securities and Exchange Commission (“SEC”).
As a result of the Theraplant Business Combination,
the Company is the acquirer for accounting purposes and Theraplant is the acquiree and accounting predecessor. Theraplant was determined
to be the accounting predecessor as the activity and operations of Theraplant will constitute substantially all the activity of the consolidated
company in the period following the Theraplant Business Combination. The Company’s financial statement presentation distinguishes
the Company’s financial performance into two distinct periods, the period up to the Closing Date (labelled “Predecessor”)
and the period after that date (labelled “Successor”).
The Theraplant Business Combination was accounted
for using the acquisition method of accounting, and the Successor financial statements reflect a new basis of accounting that is based
on the fair value of the net assets acquired.
Determining the fair value of certain assets and
liabilities assumed is judgmental in nature and often involves the use of significant estimates and assumptions. See Note 2 for a discussion
of the estimated fair values of assets and liabilities recorded in connection with the Company’s acquisition of Theraplant.
As a result of the application of the acquisition
method of accounting as of the Closing Date of the Theraplant Business Combination, the accompanying Consolidated Financial Statements
include a black line division which indicates that the Predecessor and Successor reporting entities shown are presented on a different
basis and are therefore, not comparable.
The historical financial information of Greenrose
Acquisition Corp. (a special purpose acquisition company, or “SPAC”) prior to the Theraplant Business Combination has not
been reflected in the Predecessor financial statements which are the only reflective of the financial position and operating results of
Theraplant. Accordingly, no other activity of the SPAC was reported for any period prior to November 26, 2021. We round amounts in the
Financial Statements to thousands, except per unit or per share amounts or as otherwise stated. We calculate all percentages, per-unit,
and per-share data from the underlying whole-dollar amounts. Thus, certain amounts may not foot, cross foot, or recalculate based on reported
numbers due to rounding. Unless otherwise indicated, all references to years are to our fiscal year, which ends on December 31.
Basis of Consolidation
The accompanying condensed consolidated financial
statements include the accounts of the Company and its subsidiaries, Theraplant and True Harvest as well as their wholly owned subsidiaries.
All intercompany transactions and balances have been eliminated in consolidation.
Correction of Immaterial Errors
During the closing process of third quarter ended
September 30, 2022, the Company identified an error in the accounting treatment of the deferred cash payment to Theraplant and the True
Harvest convertible promissory note, which should have been accounted for in a similar manner. The error was a discrepancy in the accounting
treatment of the Convertible Promissory Note (“Deferred Cash Payment”) dated November 26, 2021, in the original amount of
$10,000 thousand to Theraplant (see Note 8) and the True Harvest Convertible Promissory Note (“Convertible Promissory Note”)
dated December 31, 2021, in the original amount of $23,000 thousand (see Note 8). Both the Deferred Cash Payment and the Convertible Promissory
Note were treated as consideration and appropriately measured at FV as part of liabilities assumed in connection with the respective business
combinations of Theraplant and True Harvest. The Company has historically been recording fair value gains and losses on the Deferred Cash
Payment and Convertible Promissory Note, however, the guidance would indicate that any initial fair value discount should be recorded
using the imputed interest method and not marked-to-market on each reporting period. As a result of further investigation, the incorrect
accounting of interest and fair value gains and losses resulted in an error to net income of approximately $1,377 thousand and $2,681
thousand in Q1 and Q2 YTD FY22, respectively. The Company evaluated the revision in accordance with Accounting Standards Codification
(“ASC”) 250, Accounting Changes and Error Corrections and evaluated the materiality of the revision on prior periods’
financial statements in accordance with the Securities and Exchange Commission Staff Accounting Bulletin No. 108, Quantifying Financial
Statement Errors. The Company concluded that the revision was not material to any prior period and therefore, amendments to previously
filed reports are not required. In accordance with ASC 250, the Company has corrected the error in the period presented. The Company recorded
an out-of-period adjustment in the three and nine months ended September 30, 2022, which both increased Current Portion of Note Payable
and decreased Change in Fair Value in Financial Instruments by $1,852 thousand, and increased Interest Expense, net by $829 thousand.
This resulted in an increase in Net Loss of $2,681 thousand.
Cash and Cash Equivalents
Cash and cash equivalents include cash deposits
in financial institutions, other deposits that are readily convertible into cash, with original maturities of three months or less, and
cash held at retail locations. The Company maintains its cash in bank deposit accounts, which, at times, may exceed federally insured
limits. At September 30, 2022 and December 31, 2021 the Company had balances of cash totaling approximately $962 thousand and $7,240 thousand,
respectively. As of September 30, 2022 and December 31, 2021, we did not hold any cash equivalents.
Restricted Cash
The Company is required to maintain cash collateral
for two months of payments of the deferred cash payment incurred in connection with the Theraplant Business Combination discussed in Note
2. Accordingly, this balance contains restrictions as to the availability and usage and is classified as restricted cash in the consolidated
balance sheet. As discussed under Liquidity and Going Concern, as of September 30, 2022, the Company did not have adequate working
capital resources to satisfy our current liabilities. As a result, the Company has not been able to comply with the aforementioned covenant
of maintaining cash collateral for two months of payments of the deferred cash payment, nor the Company has been able to meet its monthly
payment obligations for the deferred cash payment (see Item 1. Legal Proceedings for further discussion of litigation filed against the
Company alleging Company’s breach of contract under the Merger Agreement).
Marketable Securities
The Company’s marketable securities are
classified as trading and reported at fair value, with changes in fair value recognized through the Change in Fair Value of Financial
Instruments on the Condensed Consolidated Statements of Operations. Fair value is based on quoted prices for identical assets in active
markets. Realized gains and losses are determined on the basis for the actual cost of the securities sold. Dividends on equity securities
are recognized in income when declared. No dividends from marketable securities were received during the period.
Accounts Receivable and Allowance for doubtful
accounts
Trade accounts receivable are recorded at the
invoiced amount and do not bear interest. Allowances for doubtful accounts reflect the Company’s estimate of amounts in its existing
accounts receivable that may not be collected due to customer claims or customer inability or unwillingness to pay. The allowance is determined
based on a combination of factors, including the Company’s risk assessment regarding the creditworthiness of its customers, historical
collection experience and length of time the receivables are past due. Though infrequent, if ever, account balances are charged off against
the allowance when the Company believes it is probable the receivable will not be recovered. No allowance for doubtful accounts was required
as of September 30, 2022 or December 31, 2021.
Prepaid and Other Current Assets
Prepaid and other current assets consist of prepaid
insurance premiums, other receivables, and packaging supplies. The Company pays for packaging and other similar products used to finish
inventory well in advance of receipt of the goods.
Inventories
The Company’s inventories include the direct
costs of seeds, labor, and growing materials, indirect costs such as utilities, labor, depreciation and overhead costs, and subsequent
costs to prepare the products for ultimate sale, which include direct costs such as materials and direct labor, and indirect costs such
as utilities and indirect labor. All direct and indirect costs related to inventory are capitalized when they are incurred, and they are
subsequently classified to Cost of goods sold in the Condensed Consolidated Statements of Operations. Inventories purchased from third
parties, which include work in process, finished goods, and packaging and supplies, are valued at the lower of cost and net realizable
value. Costs incurred during the growth and production process are capitalized as incurred to the extent that the cost is less than net
realizable value. Cost is determined using the weighted average costing method. Net realizable value is the estimated selling price in
the ordinary course of business, less the estimated costs to sell. The Company reviews inventories for obsolete, redundant, and slow-moving
goods and any such inventories identified are written down to net realizable value. As of September 30, 2022 and December 31, 2021 no
reserve for inventories was required.
On February 8, 2020, one of the Theraplant’s
grow rooms had a fire, destroying the plants housed within that room. The inventory was immediately adjusted down to account for the loss
of plants. The insurance company paid for the repairs to the room, and a claim is still pending for lost revenues of $1,000 thousand the
policy limit.
Property and Equipment, net
Property and equipment is stated at cost, net
of accumulated depreciation and impairment losses, if any. Expenditures that materially increase the life of the assets are capitalized.
Ordinary repairs and maintenance are expensed as incurred. Land and construction in process are not depreciated Depreciation is calculated
on a straight-line basis over the estimated useful life of the asset using the following terms and methods:
Land Improvements | |
5 Years |
Buildings and Improvements | |
10 - 39 Years |
Furniture and Fixtures | |
1 - 7 Years |
Computer Equipment and Software | |
2 - 3 Years |
Vehicles | |
3 - 8 Years |
Production and Processing Equipment | |
1 - 7 Years |
Controls | |
3 - 14 Years |
Leasehold Improvements | |
Shorter of 10 Years or Lease term |
Income Taxes
Deferred taxes are provided using an asset and
liability method whereby deferred tax assets are recognized for deductible temporary differences and operating loss carryforwards and
deferred tax liabilities are recognized for taxable temporary differences. Temporary differences are the differences between the reported
amounts of assets and liabilities and their tax basis. Deferred tax assets are reduced by a valuation allowance when, in the opinion of
management, it is more likely than not that some portion or all of the deferred tax assets will not be realized. A valuation allowance
is recorded to reduce the carrying amount of a deferred tax asset to its realizable value unless it is more likely than not that such
asset will be realized. We recognize interest and penalties associated with tax matters as part of the income tax provision, if any, and
include accrued interest and penalties with the related tax liability in the Condensed Consolidated Balance Sheet, if applicable.
Deferred tax assets and liabilities are measured
using the enacted taxes rates. The effect on deferred tax assets and liabilities of a change in tax law or tax rates is recognized in
income in the period that enactment occurs. As discussed further in Note 11, the Company is subject to the limitations of Internal Revenue
Code of 1986, as amended (“IRC”) Section 280E. Prior to the Theraplant Business Combination, the Predecessor’s members
had elected to have the Predecessor treated as a partnership for income tax purposes. As such, the items of income, loss, deduction, and
credit are passed through to, and taken into account by, the Predecessor’s members in computing their own taxable income.
The Predecessor is subject to the limits of IRC
Section 280E under which it is only allowed to deduct expenses directly related to sales of product. This results in permanent differences
between ordinary and necessary business expenses deemed non-allowable under IRC Section 280E.
The deferred tax amounts contained within Condensed
Consolidated Balance Sheets arise from timing differences between federal and state depreciation regulations. There are no deferred tax
liabilities on the Condensed Consolidated Balance Sheets as of September 30, 2022 and December 31, 2021.
Revenue Recognition
For the periods ended September 30, 2022 and the
periods ended September 30, 2021, the Company has adopted Financial Accounting Standards Board (“FASB”) Audit Standards Update
(“ASU”) 2014-09, “Revenue from Contracts with Customers” and all the related amendments, which are also codified
into Accounting Standards Codification (“ASC”) 606, “Revenue from Contracts with Customers”.
Through application of this standard, the Company
recognizes revenue to depict the transfer of promised goods or services to the customer in an amount that reflects the consideration to
which the Company expects to be entitled in exchange for those goods or services.
In order to recognize revenue under ASC 606, the
Company applies the following five (5) steps:
|
● |
Identify a customer along with a corresponding contract; |
|
● |
Identify the performance obligation(s) in the contract to transfer goods or provide distinct services to a customer; |
|
● |
Determine the transaction price the Company expects to be entitled to in exchange for transferring promised goods or services to a customer; |
|
● |
Allocate the transaction price to the performance obligation(s) in the contract; |
|
● |
Recognize revenue when or as the Company satisfies the performance obligation(s). |
Under Topic 606, revenue from the sale of cannabis
products is a single performance obligation and revenue is recognized at the point in time when control of the product transfers and the
Company’s obligations have been fulfilled. This generally occurs upon delivery and acceptance by the customer. Amounts disclosed
as revenue are net of allowances, discounts, and rebates. Payment is typically due upon transferring the goods to the customer or within
a specified time period permitted under the Company’s policy. Sales discounts were not material during the three and nine month
periods ended September 30, 2022 and the three and nine month periods ended September 30, 2021.
A significant customer is defined to be those
that individually comprise 10% or more of the Company’s revenues or accounts receivable. The following table reflects the revenues
and accounts receivable for customers determined to be significant for the three months and nine months ended September 30, 2022 and September
30, 2021 and as of September 30, 2022 and December 31, 2021, respectively.
| |
Accounts Receivable | | |
Revenue For the | | |
Revenue For the | |
| |
As of | | |
Nine Months Ended | | |
Three Months Ended | |
| |
September 30, 2022 | | |
December 31, 2021 | | |
September 30, 2022 | | |
September 30, 2021 | | |
September 30, 2022 | | |
September 30, 2021 | |
Customer A | |
| 15 | % | |
| 25 | % | |
| 16 | % | |
| 27 | % | |
| 17 | % | |
| 26 | % |
Customer B | |
| 19 | % | |
| 20 | % | |
| 15 | % | |
| 17 | % | |
| 16 | % | |
| 18 | % |
Customer C | |
| * | | |
| 16 | % | |
| * | | |
| * | | |
| * | | |
| * | |
Customer D | |
| * | | |
| * | | |
| * | | |
| 15 | % | |
| * | | |
| 15 | % |
Customer F | |
| 13 | % | |
| 17 | % | |
| 12 | % | |
| 14 | % | |
| 10 | % | |
| 15 | % |
Fair Value of Financial Instruments
The carrying amounts of financial instruments,
including accounts receivable, marketable securities, accounts payable, accrued liabilities, and short-term borrowings, approximate fair
value due to the short maturity of these instruments.
It is the Company’s policy, in general,
to measure nonfinancial assets and liabilities at fair value on a nonrecurring basis. These items are not measured at fair value on an
ongoing basis but are subject to fair value adjustments in certain circumstances (such as evidence of impairment) which, if material,
are disclosed in the accompanying notes to these consolidated financial statements.
Financial instruments recorded at fair value are
classified using a fair value hierarchy that reflects the significance of the inputs to fair value measurements. The three levels of hierarchy
are:
|
Level 1: |
Unadjusted quoted prices in active markets for identical assets or liabilities; |
|
|
|
|
Level 2: |
Inputs other than quoted prices that are observable for the asset or liability, either directly or indirectly; and |
|
|
|
|
Level 3: |
Inputs for the asset or liability that are not based on observable market data. |
Use of Estimates
The preparation of consolidated financial statements
in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the condensed consolidated
financial statements and accompanying notes and related disclosures. Although these estimates are based on management’s best knowledge
of current events and actions the Company may undertake in the future, actual results ultimately may differ from the estimates.
The Company is subject to a number of risks similar
to those of other companies of similar size and having a focus on serving the cannabis industry, including limited number of suppliers,
acquisitions and integration, and government regulations.
Impairment of Long-Lived Assets
The Company accounts for its long-lived assets
such as property and equipment in accordance with FASB ASC Topic No. 360, “Accounting for the Impairment or Disposal of Long-lived
Assets” (“ASC 360”).
Management reviews long-lived assets for impairment
whenever changes in events or circumstances indicate the assets may be impaired, but no less frequently than annually. Pursuant to ASC
360, an impairment loss is to be recorded when the net book value of an asset exceeds the undiscounted cash flows expected to be generated
from the use of the asset. If an asset is determined to be impaired, the asset is written down to its realizable value, and the loss is
recognized in the consolidated statement of operations in the period when the determination is made. No impairment charges for long-lived
assets have been recorded for the three and nine months ended September 30, 2022 and 2021.
Concentration of Credit Risk
Financial instruments that potentially subject
the Company to concentrations of credit risk consist of cash accounts in a financial institution, which, at times may exceed the Federal
Depository Insurance Coverage of $250 thousand. The Company has not experienced losses on these accounts and management believes the Company
is not exposed to significant risks on such accounts.
Advertising
Advertising amounts are expensed as incurred.
Advertising expenses for the three and nine months ended September 30, 2022 totaled $25 thousand $78 thousand, respectively. Advertising
expenses for the three and nine month period ended September 30, 2021, totaled $12 thousand and $199 thousand, respectively.
Earnings Per Share
Basic and diluted earnings per share (“EPS”)
are calculated in accordance with ASC 260, Earnings Per Share (“ASC 260”). Basic EPS is calculated by dividing net income
(loss) attributable to the Company by the weighted average number of common shares outstanding during the year. Diluted EPS is calculated,
if applicable, by adjusting net income (loss) attributable to the Company and the weighted average number of common shares, taking into
effect all potential diluted common shares. Shares of restricted stock granted by us are considered to be legally issued and outstanding
as of the date of grant, notwithstanding that the shares remain subject to the risk of forfeiture if the vesting conditions for such shares
are not met, and are included in the number of shares outstanding disclosed on the cover page of this Quarterly Report on Form 10-Q. Weighted-average
common shares outstanding excludes time-based and performance-based unvested shares of restricted Class A common stock, as restricted
shares are treated as issued and outstanding for financial statement presentation purposes only after such shares have vested and, therefore,
have ceased to be subject to a risk of forfeiture.
Segment Reporting
Operating segments are identified as components
of an enterprise where separate discrete financial information is available for evaluation by the chief operating decision maker in making
decisions on how to allocate resources and assess performance. The Company operates in a single segment which is its only reportable segment:
the production and sale of cannabis products. The Company has determined that its Chief Operating Decision Maker (“CODM”)
is its Interim Chief Executive Officer, and the CODM makes decisions based on the Company as a whole. In determining the Company’s
segment, Management considered differences in products, geographic regions for which it operates in, and the differing regulatory environments.
Goodwill and Indefinite Life Intangible
Assets
Goodwill, represents the excess of purchase price
over the fair value of net assets acquired, is carried at cost in a transaction accounted for as a business combination in accordance
with ASC 805. Goodwill is not amortized; rather, it is subject to a periodic assessment for impairment by applying a fair value-based
test. The Company is organized in one reporting unit and evaluates the goodwill for the Company as a whole. Goodwill is assessed for impairment
on an annual basis as of November 1st of each year or more frequently if events or changes in circumstances indicate that the asset might
be impaired. Under the authoritative guidance issued by the FASB, the Company has the option to first assess the qualitative factors to
determine whether it is more likely than not that the fair value of the reporting unit is less than its carrying amount as a basis for
determining whether it is necessary to perform a quantitative goodwill impairment test. If the Company determines that it is more likely
than not that the fair value of a reporting unit is less than its carrying amount, then the goodwill impairment test is performed. The
goodwill impairment test requires the Company to estimate the fair value of the reporting unit and to compare the fair value of the reporting
unit with its carrying amount. If the fair value exceeds the carrying amount, then no impairment is recognized. If the carrying amount
recorded exceeds the fair value calculated, then an impairment charge is recognized for the difference. During the third quarter ended
September 30, 2022, the Company performed a qualitative assessment of its reporting units to evaluate whether it is more likely than
not that the fair value of a reporting unit is less than its carrying amount. As part of that evaluation, the Company considered the sustained deterioration of
its stock price, changes in key members of executive management and the results of its budget to actuals to determine a quantitative test
must be performed. As a result of the quantitative goodwill impairment assessment performed, the Company recognized goodwill
impairment charges of $7,435 thousand and $25,719 thousand to the Theraplant and True Harvest reporting units, respectively.
The total goodwill impairment charge for the three and nine months ended September 30, 2022 of $33,154 thousand is included within
asset impairment in the Condensed Consolidated Statements of Operations.
Indefinite life intangible assets are carried
at cost less accumulated impairment losses. The Company reviews the classification each reporting period to determine whether the assessment
made about the useful life is still appropriate. Any change is accounted for on a prospective basis as a change in estimate. Goodwill
is currently the only indefinite lived intangible asset.
Stock-Based Compensation
The Company sponsors an equity incentive plan
(the “Plan”) in which certain employees and non-employee directors participate. The Plan is administered by the compensation
committee of the board of directors of the Company (the “Compensation Committee”). The Company measures the cost of services
received in exchange for an award of equity instruments (typically restricted stock unit awards (“RSUs”) and stock options)
based on the grant-date fair value of the awards issued under the Plan that are equity classified. Liability classified RSUs are valued
based on the fair value of the stock at each reporting period until the date of settlement with changes in fair value recognized as increases
or decreases in stock-based compensation expense in the accompanying consolidated statements of comprehensive income (loss) each reporting
period over the period during which an employee or non-employee director is required to provide service in exchange for the awards, usually
the vesting period. The fair value of the stock options is calculated using the Black-Scholes option-pricing model, and forfeitures are
accounted for as they occur. Refer to Note 14 for further details of activity related to the Plan.
Derivative Liabilities
The Company accounts for warrants as either equity-classified
or liability-classified instruments based on an assessment of the instruments’ specific terms and applicable authoritative guidance
in ASC 480, Distinguishing Liabilities from Equity (“ASC 480”) and ASC 815, Derivatives and Hedging (“ASC
815”). The assessment considers whether the instruments are freestanding financial instruments pursuant to ASC 480, meet the definition
of a liability pursuant to ASC 480, and whether the instruments meet all of the requirements for equity classification under ASC 815,
including whether the instruments are indexed to the Company’s own common shares and whether the instrument holders could potentially
require “net cash settlement” in a circumstance outside of the Company’s control, among other conditions for equity
classification. This assessment, which requires the use of professional judgment, is conducted at the time of warrant issuance and as
of each subsequent quarterly period end date while the instruments are outstanding.
For issued or modified instruments that meet all
the criteria for equity classification, the instruments are required to be recorded as a component of additional paid-in capital at the
time of issuance. For issued or modified instruments that do not meet all the criteria for equity classification, the instruments are
required to be recorded at their initial fair value on the date of issuance, and each balance sheet date thereafter. Changes in the estimated
fair value of the instruments are recognized as a non-cash gain or loss on the statements of operations.
Acquisitions
The Company accounts for business combinations
using the acquisition method of accounting. On the date of the acquisition, we allocate the purchase price to the assets acquired and
liabilities assumed at their estimated fair values. Goodwill on the acquisition date is measured as the excess of the purchase price over
the fair values of assets acquired and liabilities assumed. While we use our best estimates and assumptions to accurately value assets
acquired and liabilities assumed at the acquisition date as well as contingent consideration, where applicable, our estimates are subject
to refinement. As a result, during the measurement period, which may be up to one year from the acquisition date, we record adjustments
to the assets acquired and liabilities assumed with corresponding adjustments to goodwill. We recognize subsequent changes in the estimate
of the amount to be paid under contingent consideration arrangements in the accompanying Consolidated Statements of Operations. We expense
acquisition-related costs as incurred.
For acquisitions that are not deemed to be businesses,
the assets acquired are recognized based on their cost to the Company as the acquirer and no gain or loss is recognized. The cost of assets
acquired in a group is allocated to the individual assets within the group based on their relative fair values and does not give rise
to goodwill. Transaction costs related to acquisitions of assets are included in the cost basis of the assets acquired.
Contingencies and Litigation
The Company may be subject to lawsuits, investigations,
and other claims related to employment, commercial, and other matters that arise out of operations in the normal course of business. We
accrue loss contingencies when losses become probable and are reasonably estimable. If the reasonable estimate of the loss is a range
and no amount within the range is a better estimate, the minimum amount of the range is recorded as a liability. We recognize legal costs
as an expense in the period incurred.
Recently Adopted Accounting Pronouncements
In August 2020, the FASB issued ASU 2020-06, “Debt-Debt
with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging-Contracts in Entity’s Own Equity (Subtopic 815-40):
Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity” (“ASU 2020-06”), which simplifies
accounting for convertible instruments by removing major separation models required under current GAAP. ASU 2020-06 removes certain settlement
conditions that are required for equity contracts to qualify for the derivative scope exception, and also eliminates the treasury stock
method to calculate diluted earnings per share for convertible instruments and requires the use of the if-converted method. ASU 2020-06
is effective for fiscal years beginning after December 15, 2023 for smaller reporting companies, including interim periods within those
fiscal years, with early adoption permitted. The Company elected to early adopt ASU 2020-06 as of December 31, 2021. The adoption of the
standard did not have a material impact on the Company’s financial position, results of operations or cash flows.
New Accounting Pronouncements
In February 2016, the FASB issued ASU 2016-02,
Leases (Topic 842) (“ASC 842”), which will replace ASC 840, “Leases”. This standard requires a lessee to recognize
assets and liabilities for all leases with a term of more than twelve months unless the underlying asset is of low value. A lessee is
required to recognize a right-of-use asset representing its right to use the underlying asset and a lease liability representing its obligation
to make lease payments. For emerging growth companies adopting under the private company timeline, the standard will be effective for
annual periods beginning on or after December 15, 2021, with earlier application permitted. The standard requires a modified retrospective
approach for leases that exist or are entered into after the beginning of the earliest comparative period in the financial statements.
Management is currently evaluating the impact of this pronouncement and expects to record additional lease liabilities and corresponding
right-of-use assets related to the leased facility at True Harvest. However, management does not believe adoption of the standard would
have a material effect on the Company’s operating results.
In June 2016, the FASB issued ASC 2016-13, Financial
Instruments - Credit Losses (Topic 326), Measurement of Credit Losses on Financial Instruments. ASU 2016-13 requires entities to measure
all expected credit losses for most financial assets held at the reporting date based on an expected loss model which includes historical
experience, current conditions, and reasonable and supportable forecasts. Companies will now use forward-looking information to better
form their credit loss estimates. ASU 2016-13 also requires enhanced disclosures to help financial statement users better understand significant
estimates and judgements used in estimating credit losses, as well as the credit quality and underwriting standards of a company’s
portfolio. For emerging growth companies, ASU 2016-13 is effective for annual periods beginning after December 15, 2022. Management does
not believe that this pronouncement, if currently adopted, would have a material effect on the Company’s consolidated financial
statements.
In November 2018 and April 2019, the FASB issued
ASU 2018-19, Codification Improvements to Topic 326, Financial Instruments - Credit Losses and ASU 2019-04, Codification Improvements
to Topic 326, Financial Instruments - Credit Losses, Topic 815, Derivatives and Hedging, and Topic 825, Financial Instruments, respectively.
These amendments add clarity to certain areas within ASU 2016-13. In May 2019, the FASB issued ASU 2019-05, Financial Instruments - Credit
Losses (Topic 326), Target Transition Relief, which provided transition relief for entities adopting ASU 2016-13 by allowing the election
of the fair value option on certain financial instruments. The effective date and the transition methodology for the amendments in these
updates are the same as in ASU 2016-13. Management does not believe that this pronouncement, if currently adopted, would have a material
effect on the Company’s consolidated financial statements.
In November 2019, the FASB issued ASU 2019-11,
Codification Improvements to Topic 326, Financial Instruments - Credit Losses. This ASU addresses issues raised by stakeholders during
the implementation of ASU No. 2016-13, Financial Instruments - Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments.
Among other narrow-scope improvements, the new ASU clarifies guidance around how to report expected recoveries. “Expected recoveries”
describes a situation in which an organization recognizes a full or partial write-off of the amortized cost basis of a financial asset,
but then later determines that the amount written off, or a portion of that amount, will in fact be recovered. While applying the credit
losses standard, stakeholders questioned whether expected recoveries were permitted on assets that had already shown credit deterioration
at the time of purchase (also known as purchased credit-deteriorated (“PCD”) assets). In response to this question, the ASU
permits organizations to record expected recoveries on PCD assets. In addition to other narrow technical improvements, the ASU also reinforces
existing guidance that prohibits organizations from recording negative allowances for available-for-sale debt securities. The ASU includes
effective dates and transition requirements that vary depending on whether or not an entity has already adopted ASU 2016-13. Management
does not believe that this pronouncement, if currently adopted, would have a material effect on the Company’s consolidated financial
statements.
In March 2020, the FASB issued ASU 2020-04, Reference
Rate Reform (Topic 848): Facilitation of the Effects of Reference Rate Reform on Financial Reporting (“ASU 2020-04”), which
provides companies with optional financial reporting alternatives to reduce the cost and complexity associated with the accounting for
contracts and hedging relationships affected by reference rate reform. This guidance is effective as of March 12, 2020 through December
31, 2022. Subsequently in January 2021, the FASB issued ASU 2021-01, Reference Rate Reform (Topic 848), which clarifies ASU 2020-04 and
provides certain optional expedients that allow derivative instruments impacted by changes in the interest rate used for margining, discounting
or contract price alignment to qualify for certain optional relief. ASU 2021-01 is effective in the same timeframe as ASU 2020-04. The
relief offered by this guidance, if adopted, is available to companies for the period March 12, 2020 through December 31, 2022. Management
does not believe that this pronouncement, if currently adopted, would have a material effect on the Company’s consolidated financial
statements.
In May 2021, the FASB issued ASU 2021-04, “Earnings
Per Share (Topic 260), Debt-Modifications and Extinguishments (Subtopic 470-50), Compensation-Stock Compensation (Topic 718), and Derivatives
and Hedging-Contracts in Entity’s Own Equity (Subtopic 815-40)”. ASU 2021-04 reduces diversity in an issuer’s accounting
for modifications or exchanges of freestanding equity-classified written call options (for example, warrants) that remain equity classified
after modification or exchange. ASU 2021-04 provides guidance for a modification or an exchange of a freestanding equity-classified written
call option that is not within the scope of another Topic. It specifically addresses: (1) how an entity should treat a modification of
the terms or conditions or an exchange of a freestanding equity-classified written call option that remains equity classified after modification
or exchange; (2) how an entity should measure the effect of a modification or an exchange of a freestanding equity-classified written
call option that remains equity classified after modification or exchange; and (3) how an entity should recognize the effect of a modification
or an exchange of a freestanding equity-classified written call option that remains equity classified after modification or exchange.
ASU 2021-04 will be effective for all entities for fiscal years beginning after December 15, 2021. An entity should apply the amendments
prospectively to modifications or exchanges occurring on or after the effective date of the amendments. Early adoption is permitted, including
adoption in an interim period. Management does not believe that this pronouncement, if currently adopted, would have a material effect
on the Company’s consolidated financial statements.
2. Business Combinations
Theraplant, LLC
On November 26, 2021, the Company consummated
the Theraplant Business Combination. Under the terms of the acquisition, the Company paid consideration of $153,040 thousand at close,
consisting of $91,196 thousand in cash, $43,500 thousand in fair value of shares issued of the Company’s common stock, $9,616 thousand
in the form of a convertible note, paid down $6,754 thousand of outstanding debt and agreed to pay an incremental $1,975 thousand based
upon the sale of an investment and certain tax reimbursements on the date of the transaction.
This acquisition qualified as a business combination
in accordance with ASC 805, Business Combinations (“ASC 805”). In accordance with the ASC 805, acquisition method of accounting,
the purchase price allocation of assets acquired, and liabilities assumed of Theraplant are presented based on their estimated fair values
as of the Closing. ASC 805 establishes a measurement period to provide the Company with a reasonable amount of time to obtain the information
necessary to identify and measure various items in a business combination and cannot extend beyond one year from the acquisition date.
Accordingly, the Company recorded an allocation of the acquisition consideration to Theraplant’s identified tangible and identifiable
intangible assets acquired and liabilities assumed based on their fair values as of the Closing Date. The excess of the acquisition consideration
over the fair value of the assets acquired and liabilities assumed was recorded as goodwill.
Preliminary Purchase Price Allocation
The following is a summary of the estimated fair
values of the assets acquired and liabilities assumed (in thousands) as of the acquisition date on November 26, 2021:
Trade receivables | |
$ | 1,425 | |
Inventory | |
| 7,965 | |
Other Current Assets | |
| 593 | |
Fixed Assets | |
| 16,074 | |
Leafline Industries, LLC | |
| 2,259 | |
Intangible assets | |
| 107,000 | |
Accounts payable and other liabilities | |
| (1,025 | ) |
Accrued Liabilities | |
| (1,173 | ) |
Net identifiable assets acquired | |
| 133,118 | |
Goodwill | |
| 19,922 | |
Total acquisition consideration | |
$ | 153,040 | |
The provisional fair values allocated to identifiable
intangible assets and their estimated useful lives are as follows:
| |
Fair Value | | |
Useful Life |
| |
(In Thousands) | | |
(In Years) |
Trade name | |
$ | 4,000 | | |
3 |
Customer relationships | |
| 23,000 | | |
5 |
Licenses | |
| 80,000 | | |
10 |
Total | |
$ | 107,000 | | |
|
The assessment of fair value is preliminary and
is based on information that was available to management and through the date these financial statements were available to be issued.
If additional information of events or circumstances that existed at the acquisition date becomes available to management related to assets
acquired or liabilities assumed subsequent to this preliminary assessment of fair value but not later than one year after the date of
the acquisition, measurement period adjustments will be recorded in the period in which they are determined, as if they had been completed
at the acquisition date.
Acquired personal property assets primarily consist
of a furniture and fixtures, computer equipment and software, vehicles and production and processing equipment (“Personal Property”),
which were valued primarily using a cost approach to estimate the replacement cost of the assets and consideration of depreciation based
on the effective age of the asset. Acquired real property assets consist primarily of building and improvements as well as some land and
land improvements (“Real Property”), which were valued based on a combination of the cost comparison and sales approaches.
The cost approach estimated the replacement cost of the assets and consideration of an appropriate allowance for depreciation based on
the effective ages of the assets relative to the expected physical lives and conditions of the assets while the sales comparison approach
values similar properties that have been sold within a reasonable period from the valuation date.
Identifiable intangible assets acquired consist
of customer relationships, trade names and cannabis licenses. The customer relationships were valued using the lost profits method which
applies a with and without key customer scenario to determine the value of such relationships to the Company. The Company determined the
useful life of the customer relationships to be 5 years based on similar market participant studies and the length of historical customer
relationships. The trade name was valued using the relief-from-royalty method. The Company determined the useful life of the trade name
to be 3 years because of the anticipated future use of the trade name and industry norms. The cannabis licenses were valued using the
multi-period excess earnings method. The Company determined the useful life of the cannabis licenses to be 10 years as similar to other
market participants within the industry. The identifiable intangible assets are amortized using the straight-line method over their respective
useful lives.
Goodwill is recognized as the excess of consideration
over the net assets acquired of Theraplant and represents the value derived by Theraplant’s market share and expected growth in
the market. During the nine months ended September 30, 2022, the Company recorded a measurement period purchase accounting adjustment
of $247 thousand related to certain fixed assets purchased by the sellers on behalf of the Company, with a related impact to goodwill.
Further, the Company recorded an impairment to Goodwill of $7,435 thousand during the three months ended September 30, 2022 (see Note
5).
True Harvest, LLC
On December 31, 2021, the Company closed its previously
announced acquisition of the assets of Arizona-based True Harvest, LLC. Under the terms of the acquisition, The Company paid total consideration
of $68,671 thousand, including $12,500 thousand in cash, $20,892 thousand in the form of a convertible note, and $14,399 thousand in fair
value of shares issued of the Company’s common stock. In addition, Contingent upon True Harvest achieving a certain price point
per pound of cannabis flower relative to total flower production within 36 months of the closing of the transaction, the Company will
pay additional consideration of up to $35,000 thousand in the form of an earnout, payable in shares of common stock of the Company. The
fair value of such contingent consideration was $20,880 thousand and is included in consideration transferred. Up to 1,100,000 shares
are contingently returnable to Greenrose if the Greenrose common stock price reaches $12.50 per share for 20 consecutive trading days,
and the fair value of such contingently returnable shares has been determined to be $0 as of the date of the transaction.
This acquisition qualified as a business combination
in accordance with ASC 805. In accordance with the ASC 805, acquisition method of accounting, the purchase price allocation of
assets acquired, and liabilities assumed of True Harvest are presented based on their estimated fair values as of the Closing. ASC 805
establishes a measurement period to provide the Company with a reasonable amount of time to obtain the information necessary to identify
and measure various items in a business combination and cannot extend beyond one year from the acquisition date. Accordingly, the Company
recorded an allocation of the acquisition consideration to True Harvest’s identified tangible and identifiable intangible assets
acquired and liabilities assumed based on their fair values as of the Closing Date. The excess of the acquisition consideration over the
fair value of the assets acquired and liabilities assumed was recorded as goodwill. During the nine months ended September 30, 2022, the
Company recorded a measurement period purchase accounting adjustment of $5,620 thousand related to the True Harvest acquisition, with
a related impact to goodwill. Further, the Company recorded an impairment to Goodwill of $25,719 thousand during the three months ended
September 30, 2022 (see Note 5).
Preliminary Purchase Price Allocation
The following is a summary of the estimated fair
values of the assets acquired and liabilities assumed as of the acquisition date on December 31, 2021 without consideration of any measurement
period adjustments which are reflected in Note 5:
(in thousands) | |
| | |
Inventory | |
$ | 4,705 | |
Fixed assets | |
| 8,780 | |
Other Assets | |
| 50 | |
Intangible assets | |
| 8,000 | |
Note
Payable | |
| (4,600 | ) |
Net identifiable assets acquired | |
| 16,935 | |
Goodwill | |
| 51,736 | |
Total
acquisition consideration | |
$ | 68,671 | |
The provisional fair values allocated to identifiable
intangible assets and their estimated useful lives are as follows:
| |
Fair Value | | |
Useful Life |
| |
(In Thousands) | | |
(In Years) |
Trade name | |
$ | 2,000 | | |
3 |
Customer relationships | |
| 6,000 | | |
5 |
Total | |
$ | 8,000 | | |
|
The assessment of fair value is preliminary and
is based on information that was available to management and through the date these financial statements were available to be issued.
If additional information of events or circumstances that existed at the acquisition date becomes available to management related to assets
acquired or liabilities assumed subsequent to this preliminary assessment of fair value but not later than one year after the date of
the acquisition, measurement period adjustments will be recorded in the period in which they are determined, as if they had been completed
at the acquisition date.
Acquired personal property assets primarily consist
of a furniture and fixtures, computer equipment and software, vehicles and production and processing equipment (“Personal Property”),
which were valued primarily using a cost approach to estimate the replacement cost of the assets and consideration of depreciation based
on the effective age of the asset.
Identifiable intangible assets acquired consist
of customer relationships and trade names. The customer relationships were valued using the lost profits method which applies a with and
without key customer scenario to determine the value of such relationships to the Company. The Company determined the useful life of the
customer relationships to be 5 years based on similar market participant studies and the length of historical customer relationships.
The trade name was valued using the relief-from-royalty method. The Company determined the useful life of the trade name to be 3 years
because of the anticipated future use of the trade name and industry norms. The identifiable intangible assets are amortized using the
straight-line method over their respective useful lives.
Goodwill is recognized as the excess of consideration
over the net assets acquired of True Harvest and represents the value derived by True Harvest’s market share and expected growth
in the market.
3. Inventories
At September 30, 2022 and December 31, 2021 the Company’s inventories
include the following:
| |
September 30, | | |
December 31, | |
(in thousands) | |
2022 | | |
2021 | |
Raw Materials | |
$ | 1,484 | | |
$ | 776 | |
Work In Process | |
| 6,848 | | |
| 9,555 | |
Finished Goods | |
| 3,546 | | |
| 2,182 | |
Total Inventories | |
$ | 11,878 | | |
$ | 12,513 | |
4. Property and Equipment
At September 30, 2022 and December 31, 2021, the Company’s property
and equipment consisted of the following:
| |
September 30, | | |
December 31, | |
(in thousands) | |
2022 | | |
2021 | |
Land | |
$ | 700 | | |
$ | 700 | |
Land Improvements | |
| 370 | | |
| 370 | |
Buildings and Improvements | |
| 12,442 | | |
| 12,229 | |
Furniture and Fixtures | |
| 323 | | |
| 323 | |
Computer Equipment and Software | |
| 51 | | |
| 32 | |
Vehicles | |
| 109 | | |
| 68 | |
Production and Processing Equipment | |
| 5,580 | | |
| 5,036 | |
Leasehold Improvements | |
| 7,169 | | |
| 6,444 | |
Construction in Progress | |
| 19 | | |
| 91 | |
Total Property and Equipment, Gross | |
| 26,763 | | |
| 25,293 | |
Less accumulated depreciation | |
| (2,092 | ) | |
| (84 | ) |
Property and Equipment, Net | |
$ | 24,671 | | |
$ | 25,209 | |
Depreciation expense for the period three and
nine months ended September 30, 2022 totaled $711 thousand and $2,008 thousand, respectively, and $693 thousand and $1,945 thousand, was
capitalized to inventory, respectively. Depreciation expense for the period three and nine months ended September 30, 2021 totaled $205
thousand and $607 thousand and, respectively, and $195 thousand and $576 thousand, was capitalized to inventory, respectively. In conjunction
with the Theraplant Business Combination and True Harvest Acquisition, the basis of all property and equipment was recognized at fair
value in purchase accounting and therefore, no assets were carried over with accumulated depreciation.
There were no fixed asset impairments for the
three or nine months ended September 30, 2022 and September 30, 2021.
5. Goodwill and Intangible Assets, Net
During the nine months ended 2022, the Company
recorded a total measurement period adjustment of $5,867 thousand to decrease the contingent consideration for the True Harvest Acquisition
and to reflect property and equipment purchased by the sellers of Theraplant, with a corresponding decrease to goodwill. The adjustment
is related to the reduction of the sales and production calculation for the contingent consideration due to facts and circumstances that
existed as of the balance sheet date but were not known. Additionally, the Company recorded a total impairment loss of $33,154 thousand.
A roll forward of goodwill is as follows:
(in thousands) | |
Successor | |
Balance as of December 31, 2021 | |
$ | 71,658 | |
Measurement Period Adjustment | |
| (5,867 | ) |
June 30, 2022 | |
$ | 65,791 | |
Impairment Loss Adjustment | |
| (33,154 | ) |
September 30, 2022 | |
$ | 32,637 | |
No such adjustments were recorded as of December
31, 2021.
Intangible assets, net, consisted of the following:
| |
September 30, 2022 | | |
December 31, 2021 | |
Intangible assets at September 30, 2022 (in thousands) | |
Amount | | |
Accumulated Amortization | | |
Net Carrying Value | | |
Amount | | |
Accumulated Amortization | | |
Net Carrying Value | |
Trade Names | |
$ | 6,000 | | |
$ | 1,626 | | |
$ | 4,374 | | |
$ | 6,000 | | |
$ | 126 | | |
$ | 5,874 | |
Customer Relationships | |
| 29,000 | | |
| 4,784 | | |
| 24,216 | | |
| 29,000 | | |
| 434 | | |
| 28,566 | |
Licenses | |
| 80,000 | | |
| 6,756 | | |
| 73,244 | | |
| 80,000 | | |
| 756 | | |
| 79,244 | |
| |
$ | 115,000 | | |
$ | 13,166 | | |
$ | 101,834 | | |
$ | 115,000 | | |
$ | 1,316 | | |
$ | 113,684 | |
Indicators of impairment were identified for the
intangible asset values as of September 30, 2022, as such the Company performed a recoverability analysis. Per the results of the recoverability
analysis, the Company concluded the undiscounted cash flows exceeded the carrying value of the asset groups and, therefore, an impairment
did not need to be recorded as of September 30, 2022.
Amortizable trade name intangible assets stayed
consistent from December 31, 2021. The weighted average amortization period for the trade name, customer relationships and licenses were
three years, five years and ten years, respectively. For the Successor period, the balance of the intangible assets was recorded at fair
value as a result of the Theraplant Business Combination as described in Note 1 and Note 2.
Amortization expense is classified in depreciation
and amortization on the consolidated statements of operations. Amortization expense of the trade name intangible assets amounted to $500
thousand, customer relationships amortization amounted to $1,450 thousand and license amortization amounted to $2,000 thousand in the
three months ended September 30, 2022. Amortization expense of the trade name intangible assets amounted to $1,500 thousand, customer
relationships amortization amounted to $4,350 thousand and license amortization amounted to $6,000 thousand in the nine months ended September
30, 2022. Estimated future amortization expense is as follows:
| |
Successor | |
(in thousands) | |
As of September 30, 2022 | |
Remaining 2022 | |
$ | 3,950 | |
2023 | |
| 15,800 | |
2024 | |
| 15,674 | |
2025 | |
| 13,800 | |
2026 | |
| 13,366 | |
Thereafter | |
| 39,244 | |
Total | |
$ | 101,834 | |
6. Accounts Payable and Accrued Expenses
Accounts Payable and current accrued expenses
and other consisted of the following:
(in thousands) | |
As of September 30, 2022 | | |
As of December 31, 2021 | |
Accounts payable | |
$ | 4,617 | | |
$ | 1,530 | |
Accrued payroll liabilities | |
| 312 | | |
| 198 | |
Accrued expense | |
| 4,691 | | |
| 17,145 | |
Deferred revenue | |
| 18 | | |
| 39 | |
Accrued interest | |
| 5,855 | | |
| 4 | |
Total accounts payable and accrued expenses | |
$ | 15,493 | | |
$ | 18,916 | |
As of September 30, 2022, the accrued expenses
primarily consists of $3,860 thousand relates to closing fees owed to the Lender of the Term Loan and Delayed Draw Term Loan as further
discussed in Note 8, and other ordinary course business expenses.
7. Amount Due to Prior Members
The Company acquired an investment in Leafline
Industries, LLC (“Leafline”) in connection with the Theraplant Business Combination, a Minnesota-based medical cannabis cultivator,
processor, and retailer. During negotiations of the final merger consideration for Theraplant, it was announced that Leafline would be
acquired by GreenThumb Industries, Inc. (“GreenThumb”). The Company agreed to pay, as consideration for Theraplant, 50% of
the proceeds for the investment in Leafline after receipt of the proceeds.
The Company determined the enterprise value of
Leafline to be $161,000 thousand. The enterprise value is based on the merger consideration for Leafline. The Company acquired 1.52% of
Leafline’s equity through the Theraplant acquisition. In connection with the business combination accounting, the Company recorded
the Leafline investment at its fair value of $2,259 thousand. The Company included 50% of the fair value of the Leafline investment as
consideration for Theraplant. Additionally, the Company has a $1,130 thousand liability for the portion of proceeds from the Leafline
investment owed to the former shareholders of Theraplant.
On December 30, 2021, Leafline shareholders, including
the Company, completed a sale to GreenThumb for a combination of cash and share consideration. GreenThumb is a publicly traded cannabis
company and therefore, the Company has marked its investment to market based on the publicly traded stock price which resulted in $1,694
thousand of investment in GreenThumb as marketable securities on the Condensed Consolidated Balance Sheet as of December 31, 2021, respectively.
In July 2022, the Company sold the 50% of the investment owned by Greenrose; therefore, the marketable securities was reduced to $0 on
the Condensed Consolidated Balance Sheet as of September 30, 2022. As such, the remaining 50% of the GreenThumb investment is the residual
balance in the Due to Prior members on the consolidated balance sheet as of September 30, 2022.
The Amount Due to Prior members was decreased
by $341 thousand and $872 for the three and nine months ended September 30, 2022, respectively, compared to December 31, 2021 due to the
sale of the investment. As of September 30, 2022, the Company had received cash of $523 thousand with deferred cash consideration of $29
thousand still outstanding and included in Other Current Assets. Further, the Company has not remitted the consideration payment owed
to the former shareholders of Theraplant including both cash and share consideration which has been included in Amount Due to Prior Members
on the consolidated balance sheet as of September 30, 2022.
8. Notes Payable
At September 30, 2022 and December 31, 2021, note payable consisted
of the following:
| |
September 30, | | |
December 31, | |
| |
2022 | | |
2021 | |
Term Loan (“Initial Term Loan”)
dated November 26, 2021, in the original amount of $88,000 thousand, which matures November 26, 2024. Principal payments will be required
upon the first sale of recreational cannabis in the state of Connecticut. Cash interest payments will be 7.5% for the first 12
months and will be 11% for the remainder of the loan. Additionally, the Company will pay PIK interest for the first 12 months at
8.5% and the remainder of the PIK will be paid at 5%. | |
$ | 88,000 | | |
$ | 88,000 | |
| |
| | | |
| | |
Convertible Promissory note dated December 31, 2021, in
the original amount of $23,000 thousand, which matures December 15, 2024. Interest (8% per annum) payments are due monthly through December
2024. A final balloon payment of all unpaid principal accrued unpaid interest will be due on the maturity date. The holder can elect
to convert the unpaid principal and interest into shares of the Company’s common stock at $10 per share. | |
| 23,000 | | |
| 23,000 | |
| |
| | | |
| | |
Term Loan (“Delayed Draw Term Loan”) dated
December 31, 2021, in the original amount of $17,000 thousand, which matures November 26, 2024. Principal payments will be required upon the
first sale of recreational cannabis in the state of Connecticut. Cash interest payments will be 7.5% for the first 12 months and
will be 11% for the remainder of the loan. Additionally, the Company will pay PIK interest for the first 12 months at 8.5% and the
remainder of the loan PIK will be paid at 5% | |
| 17,000 | | |
| 17,000 | |
| |
| | | |
| | |
Three promissory notes: dated December 30, 2021, in the
aggregate original amount of $4,600 thousand, which mature December 30, 2023: Equal payments of principal and interest are due monthly
through December 2023. The loans each incur interest at 12% of the outstanding principal balance. | |
| 4,238 | | |
| 4,600 | |
| |
| | | |
| | |
Convertible Promissory (“Deferred Cash
Payment”) note dated November 26, 2021, in the original amount of $10,000 thousand, which matures November 26, 2022. Equal principal
and interest (9%) payments are due monthly through November 2022. The holder can elect to convert the unpaid principal and interest
into shares of the Company’s common stock at $10 per share. | |
| 7,480 | | |
| 9,167 | |
| |
| | | |
| | |
Non-interest bearing promissory note (“Imperial Note”) dated April 13, 2022, in the original amount of $10,422,750, which matures on October 15, 2023. Principal payments, payable in shares of Company stock, are due quarterly through maturity. Any remaining principal balance due at maturity. | |
| 10,098 | | |
| - | |
| |
| | | |
| | |
Secured promissory note
(“Secured Promissory Note”) dated October 12, 2022, in the original amount of $15,300 thousand, which matures October 12, 2024.
Equal principal payments are due quarterly through maturity. | |
| 15,300 | | |
| - | |
Total Notes Payable | |
| 165,116 | | |
| 141,767 | |
| |
| | | |
| | |
Add: PIK Interest | |
| 7,664 | | |
| 731 | |
Less: deferred finance costs | |
| (5,718 | ) | |
| (6,788 | ) |
Less: discount on debt | |
| (23,509 | ) | |
| (27,203 | ) |
Less: fair value adjustments (short term) | |
| (1,663 | ) | |
| (2,492 | ) |
Less: current portion | |
| (132,317 | ) | |
| (106,015 | ) |
Notes payable, net of current portion | |
$ | 9,573 | | |
$ | - | |
Event of default
As discussed further in Note 1, there is substantial
doubt about the Company’s ability to continue as a going concern. As a result of the Company not filing its annual financial statements
within 90 days from year end as well as the qualified opinion of the auditors with respect to the Company’s ability to continue
as a going concern, the Company is in technical default of the Credit Agreement. Further, the Company’s Convertible Promissory Note
and other Promissory Notes have cross default language which results in default of those notes due in the event of an uncured event of
default under the Credit Agreement; For the period ending on September 30, 2022, no event of default was declared nor was acceleration
of indebtedness been triggered by our Lenders and Agent pursuant to the Credit Agreement. However, on October 2,2022, the Lenders and
Agent declared an event of default and on October 10, 2022 an event of additional default without acceleration of indebtedness. As the
result of the notice of default and the corresponding cross defaults, we are required to classify long-term obligations as current liabilities.
All of the notes payable, except for the Imperial
Note, have been classified within current liabilities as of September 30, 2022 and December 31, 2021. On November 10, 2022, the Company,
executed the Transaction Support Agreement, Amendment No. 2 to Credit Agreement and Forbearance Agreement with our Lenders and its Agents.
See Note 17.
The principal payments reflected within this table
are based on the contractual terms within the respective agreements. The future principal payments below assume that all debt will be
paid based on the contractual repayment terms.
Nine Months Ending September 30** | |
| |
Remaining 2022 | |
$ | 9,368 | |
2023 | |
| 20,098 | |
2024* | |
| 135,650 | |
2025 | |
| - | |
2026 | |
| - | |
Thereafter | |
| - | |
| |
$ | 165,116 | |
* |
Quarterly principal payments on the Term Loans in the amount of $5,000 thousand are required at the earlier of the second full fiscal quarter following the date of the introduction and implementation of the Adult Use Cannabis market in the state of Connecticut or the ninth fiscal quarter following November 26, 2021. Since the implementation of Adult Use Cannabis in the state of Connecticut has not been completed, the Company has included all such payments assuming the ninth fiscal quarter following the Closing Date. The 2024 principal payments exclude approximately $20,835 thousand in PIK interest accrued over the life of the term loans. |
|
|
** |
The principal payments reflected within this table are based on the contractual terms within the respective agreements. Effective at the time of issuance of these financial statements, each of the debt instruments issued by the Company are in default which has triggered, each of these instruments to classified as current. The payments above do not assume that all debt will be paid in 2022 but based on the contractual repayment terms. |
On November 26, 2021, the Company entered into
a credit agreement (the “Credit Agreement”) with DXR Finance LLC (the “Agent”), and lenders DXR-GL Holdings I,
LLC, DXR-GL Holdings II, LLC, and DXR-GL Holdings III, LLC DXR Finance, LLC (collectively, the “Lender”). The Lender provided
an initial term loan (“Term Loan”) in the amount of $88,000 thousand. The funds from the Term Loan were used to fund the Theraplant
Business Combination (see Note 2). Additionally, the Credit Agreement allows for a delayed draw term loan (the “Delay Draw Term
Loan”) in amount equal to $17,000 thousand (together with the Term Loan, “Term Loans”). The funds of the Delayed Draw
Term Loan were used in the True Harvest Acquisition (see Note 2). Quarterly principal payments of $5,000 thousand are required at the
earlier of the second full fiscal quarter following the date of the introduction and implementation of the Adult Use Cannabis market in
the state of Connecticut or the ninth fiscal quarter following November 26, 2021. The term loans bear interest at fixed 16% plus a minimum
LIBOR rate of 1%. If the London interbank offered rate, or LIBOR, ceases to be published by the intercontinental exchange, or a statement
is published by the Board of Governors of the Federal Reserve of the United State or the Federal Reserve Bank of New York to similar effect,
then for the purpose of calculating the interest rate on outstanding borrowings, the new benchmark will be determined by combining the
rate of the secured overnight financings for the Federal Reserve Bank of New York with certain applicable adjustments, as determined by
DXR Finance, LLC, as agent for the loan. Of the 16% interest the Company will pay cash interest at 7.5% and payment-in-kind (PIK interest)
at 8.5% for the first year. Subsequent to the first twelve months, the Company will pay cash interest at 11% and PIK interest at 5% of
the outstanding balance. The PIK interest payments will be accrued into the outstanding balance of the loan.
In connection with the Credit Agreement, the Company
issued warrants with each of the Term Loans. Contemporaneously with the Term Loan issued on November 26, 2021, the Company issued to the
Lender 2,000,000 warrants (“Lender Warrants”) exercisable in the Company’s non-voting common stock. The warrants
have an exercise price of $0.01 and expire 10 years from the date of issuance. The warrants have a cash election feature that allows the
holder to elect cash settlement at the option of the holder.
On December 31, 2021, the Company amended the
warrant agreement by adding a price floor to the cash election feature whereas the Lender can elect to net cash settle the warrants for
an amount that is the greater of the fair market value of the Company’s share price or the price floor. The price floor starts at
$6.00 per share and increases $1.00 in each subsequent year on the initial term loan anniversary date. Additionally, the expiration date
of the warrants is now able to be extended by five successive one-year extensions if the sale of cannabis continues to be federally illegal
at the expiration date (the fifth anniversary of the issuance date and subject to five 1-year extensions at the election of the holder).
Contemporaneously with the Delayed Draw Term Loan
on December 31, 2021, the Company issued to the Lender 550,000 warrants. The terms of the warrants issued on December 31, 2021 are the
same as the warrants issued on November 26, 2021, as amended.
On September 8, 2022, the Company received notices
of exercise from the holder of the Company’s Lender Warrants. Under the terms of the Warrants, the holder elected to exercise the
Warrants by making a cash election in return for a cash payment of the Company’s common shares based on the floor amount of $6.00
per share. The Company elected to pay the holder in form of a promissory note, as the Company determined that the cash payment would result
in the Company’s liquidity being less than sufficient to enable the Company to pay its obligations in the ordinary course of business.
On October 12, 2022, simultaneously with the execution of the Forbearance Agreement (as defined and discussed in further details under
Note 17), the Company issued a secured promissory note (“Secured Promissory Note”) in the amount of $15,300 thousand to the
Warrants holders. The Secured Promissory Note matures on October 12, 2024 and principal payments of $1,913 thousand are due quarterly.
The Secured Promissory Note accrues interest daily on the basis of a 360 day year at the LIBOR rate plus 16% with a minimum LIBOR rate
of 1%; provided that upon the occurrence and during the continuance of an Event of Default (as defined in the Forbearance Agreement),
the outstanding principal amount of the Secured Promissory Note and any accrued and unpaid interest and all other overdue amounts shall
each bear interest until paid at the stated rate plus 2% per annum.
In connection with the Theraplant Business Combination,
the Company issued a $10,000 thousand deferred cash payment to the former shareholders of Theraplant convertible into shares of Greenrose
common stock. The deferred cash payment bears interest at 9% and will mature on November 26, 2022 and has been fully included in the current
portion of notes payable on the consolidated balance sheet. Equal principal and interest payments are due monthly through November 2022.
The holder has the option to convert the outstanding principal into the Company’s common stock at a conversion price is $10.00 and
the number of shares to be issued will be based on the conversion price and the outstanding principal at the time of conversion. The deferred
cash payment was included in consideration for the Theraplant Business Combination and was recorded at its initial fair value.
In connection with the True Harvest Acquisition,
the Company issued a $23,000 thousand convertible note to the former shareholders of True Harvest. The note bears interest at 9% and will
mature on December 31, 2024. Interest payments of $460 thousand are due monthly through November 2022. On December 31, 2024, the Company
will make a final “balloon” payment of all unpaid principal and accrued unpaid interest. The note holder has the option to
convert the outstanding principal into the Company’s common stock. The conversion price is $10.00 and the number of shares to be
issued will be based on the conversion price and the outstanding principal and accrued and unpaid interest at the time of conversion.
The convertible note was included in consideration for the True Harvest Acquisition and was recorded at its initial fair value.
In connection with the True Harvest Acquisition,
the Company assumed approximately $4,600 thousand of debt. The debt consisted of three promissory notes (the “Promissory Notes”).
The Promissory Notes mature December 2023 and bear interest at 12% of the outstanding loan principal. Equal interest and principal payments
are due each month.
Troubled Debt Restructuring
On April 13, 2022, the Company entered into an
amended engagement letter with Imperial, whereby the Company has engaged Imperial to serve and act as non-exclusive merger and acquisition
advisor in connection with potential (i) mergers or stock or asset acquisitions or (ii) sales or other dispositions of business or assets
of the Company involving one or more businesses engaged in the medical and/or adult-use recreational cannabis business. Simultaneously
with the entry of the Engagement Letter, Greenrose issued a non-interest bearing promissory note in the face amount of $10,423 thousand
and maturing October 15, 2023 (the “Note”) to Imperial. All fees earned and paid to Imperial by the Company under the Engagement
Letter shall reduce the principal amount owed and payable to Imperial. The shares of common stock issued in connection with the retainer
will be unregistered shares issued in a private placement exempt from registration under Section 4(a)(2) of the Securities Act of 1933,
as amended, and be subject to periodic registration rights.
The amended arrangement with Imperial constitutes
a troubled debt restructuring (“TDR”) as the Company is experiencing financial difficulties and a concession has been granted
by Imperial. When a borrower has a TDR in which the terms of its debt are modified, it should analyze the future undiscounted cash flows
to determine the appropriate accounting treatment. The recognition and measurement guidance for a TDR depends on whether the future undiscounted
cash flows specified by the new terms are greater or less than the carrying value of the debt. The Company determined that the future
undiscounted cash flows under the new terms were equal to the net carrying value of the original debt, therefore, the Company did not
recognize a gain on restructuring.
Interest expense, net
The components of interest expense, net (which
includes interest expense incurred) recognized in the consolidated statements of comprehensive income (loss) for the periods indicated
below consist of the following:
| |
Three Months Ended | | |
Nine Months Ended | |
| |
Successor | | |
Predecessor | | |
Successor | | |
Predecessor | |
| |
September 30, | | |
September 30, | | |
September 30, | | |
September 30, | |
(in thousands) | |
2022 | | |
2021 | | |
2022 | | |
2021 | |
Interest expense incurred in Initial Term Loan | |
$ | 6,088 | | |
$ | - | | |
$ | 14,461 | | |
$ | - | |
Interest expense incurred on Delayed Draw Term Loan | |
| 708 | | |
| - | | |
| 1,442 | | |
| - | |
Interest expense incurred on deferred cash payment | |
| 445 | | |
| - | | |
| 767 | | |
| - | |
Interest expense on Assumed Debt | |
| 1,042 | | |
| - | | |
| 2,189 | | |
| - | |
Misc. interest expense | |
| 1 | | |
| 58 | | |
| 19 | | |
| 135 | |
Amortization of deferred financing costs | |
| 402 | | |
| - | | |
| 1,070 | | |
| - | |
Amortization of original issue discount | |
| 1,427 | | |
| - | | |
| 3,694 | | |
| - | |
Interest expense, net | |
$ | 10,113 | | |
$ | 58 | | |
$ | 23,642 | | |
$ | 135 | |
Deferred Financing Costs and Original Issue Discount
The Company incurred and deferred approximately
$6,788 thousand of deferred financing costs and approximately $27,203 thousand of original issue discount in connection with the issuance
of the Term Loans in 2021 in connection with the Theraplant Business Combination and True Harvest Acquisition. Unamortized original issue
discount and deferred financing costs are included in the carrying value of the Term Loans as of September 30, 2022. The amortization
expense related to the deferred financing costs was $402 thousand and $1,070 thousand and the amortization of the original issue discount
was $1,427 thousand and $3,694 thousand for the three and nine months ended September 30, 2022, respectively, which has been included
within interest expense in the consolidated statement of operations. No deferred financing costs or original issue discount existed for
the three and nine months ended September 30, 2021.
9. Fair Value Measurement
The Company follows the guidance relating to fair
value measurements and disclosures with respect to financial assets and liabilities that are re-measured and reported at fair value each
reporting period, and with respect to non-financial assets and liabilities that are not required to be measured at fair value on a recurring
basis. The guidance establishes a fair value hierarchy that prioritizes the inputs to the valuation techniques used to measure fair value.
The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level I) and
the lowest priority to unobservable pricing inputs (Level III). A financial asset or liability’s level within the fair value hierarchy
is based upon the lowest level of any input that is significant to the fair value measurement in its entirety. The three levels of the
fair value hierarchy are described below:
Level I - Valuations are based on unadjusted quoted
prices in active markets for identical, unrestricted assets or liabilities;
Level II - Valuations are based on quoted prices
for similar instruments in active markets or quoted prices for identical or similar instruments in markets that are not active. Financial
asset or liabilities which are included in this category are securities where all significant inputs are observable, either directly or
indirectly; and
Level III - Prices or valuations that are unobservable
and where there is little, if any, market activity for these financial assets or liabilities. The inputs into the determination of fair
value inputs for these investments require significant management judgment or estimation. The availability of observable inputs can vary
depending on the financial asset or liability and is affected by a wide variety of factors. To the extent that valuation is based on inputs
that are less observable or unobservable in the market, the determination of fair value requires more judgment.
The fair values of the Company’s Level II
derivative instruments were determined using valuation models that use market observable inputs including interest rate curves and both
forward and spot prices for commodities. Derivative assets and liabilities included in Level II primarily represent debt and the Company’s
private warrants.
The fair values of the Company’s Level III
derivative instruments were determined using valuation models that use inputs not observed in the market including cannabis production
and both forward and spot prices for commodities. Derivative assets and liabilities included in Level III primarily represent earnout
obligation shares related to the True Harvest acquisition, warrants issued to the Lender as well as the Investor Shares.
The following table presents the Company’s
financial assets and liabilities measured at fair value on a recurring basis based upon the level within the fair value hierarchy in which
the fair value measurements fall, as of September 30, 2022:
(in thousands) | |
Level I | | |
Level II | | |
| | |
Level III | | |
| | |
Total | |
Liabilities: | |
| | |
| | |
| | |
| | |
| | |
| |
True Harvest Earnout | |
| - | | |
| - | | |
| | | |
| 56 | | |
| | | |
| 56 | |
Private Warrants Liability | |
| - | | |
| 541 | | |
| | | |
| - | | |
| | | |
| 541 | |
Total liabilities | |
$ | - | | |
$ | 541 | | |
$ | 541 | | |
| 56 | | |
$ | 56 | | |
| 597 | |
The Company has assessed that the fair value of
cash and cash equivalents, trade receivables, related party receivables, trade payables, other current liabilities, and other debt approximates
their carrying amounts largely due to the short-term maturities or recent commencement of these instruments.
The following table summarizes financial instruments
carried at amortized cost with fair values that are different than their carrying amounts:
| |
September
30, 2022 | |
Financial Assets (Liabilities) Not Measured at Fair Value | |
Carrying Amount | | |
Fair Value | |
Term Loan (see Note 8) - Level 3 | |
$ | (94,505 | ) | |
$ | (88,132 | ) |
Delayed Draw Term Loan (See Note 8) - Level 3 | |
$ | (18,111 | ) | |
$ | (16,856 | ) |
Promissory notes (See Note 8) - Level 3 | |
$ | (4,238 | ) | |
$ | (2,844 | ) |
Imperial Note (See Note 8) - Level 3 | |
$ | (10,098 | ) | |
$ | (5,278 | ) |
Deferred Cash Payment (see Note 8) – Level 3 | |
$ | (7,464 | ) | |
$ | (7,343 | ) |
True Harvest Convertible Note (see Note 8) – Level 3 | |
$ | (21,352 | ) | |
$ | (17,810 | ) |
In connection with the True Harvest Acquisition,
the Company issued contingent consideration with a value of up to $35,000 thousand (the “Earnout”). During the nine months
ended September 30, 2022, the Company recorded a measurement period adjustment of $5,867 thousand to decrease the contingent consideration
for the True Harvest acquisition, with a corresponding decrease to goodwill. The adjustment is related to the reduction of the sales and
production calculation for the contingent consideration. The consideration is contingent on the future performance of the acquired business
and its associated activities during the three-year period following the transaction. Specifically, the Earnout will be based on the average
of the Weighted Average Annual Price Points in each of the three years (the 36 Month Price Point), where Weighted Average Annual Price
Point is defined as (i) the total revenue of the Company, divided by (ii) the total weight in pounds of flower product produced. The Earnout
will then be satisfied with shares of Greenrose common stock and will be due on the earlier of (i) January 15, 2025 or (ii) the date upon
which the Seller provides Greenrose with written notice of its acceptance of the Earnout Statement and the Earnout amount calculated therein.
The fair value of the Earnout was estimated using
a Monte Carlo simulation assuming Geometric Brownian Motion (GBM) in a risk-neutral framework and is based on the present value of the
average of the simulated Earnout payments across 1,000,000 simulation paths. The primary assumptions used in the Monte Carlo simulation
include the company’s forecast of revenue and production, the correlation between these two-underlying metrics, the discount rate,
volatility, credit spread, and risk-free rate. Changes to the forecasts for the achievement of the milestones, and the estimates of the
borrowing rate can significantly affect the estimated fair value of the contingent consideration. The significant unobservable inputs
used in the analysis are detailed in the table below. During the nine months ended September 30, 2022, the Company recorded a measurement
period adjustment of $5,620 thousand to decrease the contingent consideration for the True Harvest acquisition, with a corresponding decrease
to goodwill. The Company also recorded a gain on consideration of $14,158 thousand and $15,204 thousand recognized in Other income (expense)
in the Condensed Consolidated Statement of Operations to decrease the consideration during the three and nine months ended September 30,
2022, respectively. The adjustment is related to the reduction of the sales and production calculation for the contingent consideration.
As of September 30, 2022, this contingency was measured as $56 thousand.
|
|
September 30, |
|
|
|
2022 |
|
Volatility |
|
|
21.64 |
% |
Discount Rate |
|
|
16.10 |
% |
Term (in years) |
|
|
2.25 |
|
Probability of Achievement |
|
|
0 - 100 |
% |
On November 26, 2021, in connection with the term
loan issued for the Theraplant Business combination, the Company issued certain rights to acquire up to 2,000,000 shares of the Company’s
non-voting common stock. Further, on December 31, 2021, in connection with the Delayed Draw Term Loan issued for the True Harvest Acquisition,
the Company issued certain rights to acquire up to 600,000 shares of the Company’s non-voting common stock. These warrants
were issued to DXR Holdings, collectively, referred to as the “Lender Warrants”. The Lender Warrants have an exercise price
of $0.01 per warrant (i.e., penny warrants) and the holder can exercise the right to purchase the common stock in part or in whole at
any time or from time to time. The warrants are immediately exercisable from the date of the agreement and the holder of the warrants
is allowed to transfer or assign the rights of the warrants to any person or party as long as the transfer would not violate U.S. federal
or state securities law. On December 31, 2021, the Company amended the warrants to include a price floor to the cash election feature
whereas the Holder can elect to net cash settle the warrants for an amount that is the greater of the fair market value of the Company’s
share price or the price floor. The price floor starts at $6.00 per share and increases $1.00 in each subsequent year on the initial term
loan anniversary date. Additionally, the expiration date of the warrants is now able to be extended by five successive one-year extensions
if the sale of cannabis continues to be federally illegal at the expiration date (the fifth anniversary of the issuance date and subject
to five 1-year extensions at the election of the holder).
The fair value of the Lender Warrants was estimated
using a binomial lattice model in a risk-neutral framework. The fair value was estimated by backwards inducting values in the binomial
lattice model form the final nodes to the initial node using daily time steps. The holders of the Lender Warrants have the option to extend
the life of the warrant up to 5 years. The fair value of the extension option was determined to have de minimis impact on the fair value
of the Lender Warrants. The significant unobservable inputs used in the analysis are detailed in the table below.
| |
September 30, | |
| |
2022 | |
Common Stock Price | |
$ | 1.14 | |
Risk-Free Rate | |
| 4.04 | % |
Credit Spread | |
| 13 | % |
Volatility | |
| 73.44 | % |
Dividend Yield | |
| 0.00 | % |
Refer to Note 12 for a summary of the changes
in the fair value of the Company’s Level 3 financial instruments.
During the periods presented, the Company has
not changed the manner in which it values liabilities that are measured at fair value using Level 3 inputs. The Company recognizes transfers
between levels of the fair value hierarchy as of the end of the reporting period. There were no transfers between the hierarchy levels
during the three and nine months ended September 30, 2022 and September 30, 2021.
10. Commitments and Contingencies
Contingencies
The Company’s operations are subject to
a variety of local and state regulations. Failure to comply with one or more of those regulations could result in fines, restrictions
on its operations, or losses of permits that could result in the Company ceasing operations. While management of the Company believes
that the Company is in compliance with applicable local and state regulations at September 30, 2022 and September 30, 2021, medical cannabis
regulations continue to evolve and are subject to differing interpretations. As a result, the Company may be subject to regulatory fines,
penalties, or restrictions in the future.
On January 6, 2022 (the “Termination Date”),
Futureworks LLC (“Futureworks”) notified the Company that it was terminating the Agreement and Plan of Merger (the “Merger
Agreement”), dated March 12, 2021, by and between Futureworks, the Company (formerly known as Greenrose Acquisition Corp.) and Futureworks
Holdings, Inc., a Delaware corporation and wholly-owned subsidiary of Greenrose (“FW Merger Sub”). Pursuant to the Merger
Agreement, Futureworks was expected to be merged with and into FW Merger Sub (the “Futureworks Merger”), with FW Merger Sub
surviving the Merger as a wholly owned subsidiary of Greenrose. All related ancillary agreements entered into on March 12, 2021, in connection
with the Futureworks Merger and the Purchase Agreement were also terminated on the Termination Date. The material terms and conditions
of the Merger Agreement were previously disclosed in the Current Report on Form 8-K filed by the Company with the Securities and Exchange
Commission on March 12, 2021 and are incorporated by reference herein.
Claims and Litigation
Futureworks, LLC. Reference
made to the Agreement and Plan of Merger dated as of March 12, 2021 between the Company and Futureworks LLC, a Delaware limited liability
company, which Futureworks terminated on January 6, 2021, as disclosed in the Company’s Report on Form 8-K dated January 12, 2022.
In a letter dated April 13, 2022, counsel to Futureworks alleged breach of the Futureworks Agreement and Plan of Merger by the Company
and threatened legal action if Futureworks’ purported claims are not settled. The Company believes Futureworks alleged claims lack
merit. In the event Futureworks commences an action against the Company in connection with the terminated Futureworks Agreement and Plan
of Merger, the Company believes it has meritorious defenses and will defend itself vigorously.
Theraplant, LLC. On June
1, 2022, the Company received a Legal Demand Letter from counsel to the Theraplant Selling Stockholders’ Representatives relating
to, among other things, the Company’s failure to make certain payments under the Theraplant Merger Agreement, which was previously
disclosed in the Company’s Form 8-K filed with the Securities and Exchange Commission on December 2, 2021 and is incorporated by
reference herein. The demand seeks payment of all amounts that were due.
As disclosed in the Company’s Form 8-K of
July 5, 2022, the Company, on June 28, 2022, received a complaint filed by Shareholder Representative against the Company in the Connecticut
Superior Court (the “Complaint”). In the Complaint, the Shareholder Representative generally alleges breach of contract, breach
of the covenant of good faith and fair dealing, and conversion with respect to the Theraplant Merger Agreement between the Plaintiff,
as representative of the Selling Securityholders of Theraplant, and the Company.
On August 3, 2022, Shareholder Representative filed (i) an amended
complaint against the Company (the “Amended Complaint”) and (ii) an application for prejudgment remedy seeking to attach property
of the Company to secure a requested $6,000 thousand judgment. The Amended Complaint, like the Complaint, generally alleges breach of
contract, breach of the covenant of good faith and fair dealing, and conversion and included a new allegation that the Company made payments
of up to an aggregate of $600 thousand to families of certain Greenrose officers and such payments were either excessive or for services
or work not performed. A hearing on the requested prejudgment remedy is scheduled for January 2023. The Company intends to defend itself
vigorously.
Next
Step Advisors, LLC, et al. On September 26, 2022, Next Step Advisors, LLC, M. Sipolt Marketing, Sabertooth Investments, LLC,
and True Harvest, LLC (collectively, the “Arizona Plaintiffs”), all alleged unsecured creditors of the Company, filed an
action in Arizona state court alleging breaches of contract and seeking the appointment of a receiver. On October 3, 2022, the Company
removed this action to Arizona federal court. Motions by the Arizona Plaintiffs to remand the action to Arizona state court and dismiss
the counterclaims asserted by the Company remain pending, and on November 10, 2022, the Arizona Plaintiffs filed a Motion to Dismiss
counterclaims in Arizona federal court. The Arizona Plaintiffs’ Motion claims that Arizona federal court lacks jurisdiction over
the dispute and that the matter must be litigated in Arizona state court, and also requested from the same court expedite consideration
of this Motion. The Company’s response to the Arizona Plaintiff’s latest Motion filing is due by November 25, 2022. The Company
believes it has meritorious counterclaims against the Arizona Plaintiffs as well as meritorious responses to the Arizona Plaintiff’s
pending claims. The Company intends to defend itself vigorously.
From time to time, the Company may be involved
in litigation relating to claims arising out of operations in the normal course of business. At September 30, 2022 (Successor) and 2021
(Predecessor), other than described above, there were no further pending or threatened lawsuits that could reasonably be expected to have
a material effect on the results of the Company’s consolidated operations. There are also no proceedings in which any of the Company’s
significant shareholders, officers, or affiliates are an adverse party or have a material interest adverse to the Company’s interest.
Leases
The Company manages and operates a facility located
at 4301 W. Buckeye, Phoenix, AZ (the “Facility”) to cultivate and manufacture medical marijuana since the inception of True
Harvest, expanding cultivation space within the Facility over time. The Facility is under a ten-year lease since 2017 with a ten-year
renewal option.
The Company leases the Facility from a third party
since its inception in 2015. The Company entered into a new lease agreement for the Facility in 2017 with a lease term of 10 years and
has an option to extend the lease term for a period of 10 years. Lease payments are annually escalated over the lease term and the Company
recognizes lease expense on a straight-line basis. The Company recognized lease expense or for the three and nine months ended September
30, 2022 of $365 thousand and $1,080 thousand. $349 thousand and $1,048 thousand of the lease expense was included in inventory for the
three and nine months ended September 30, 2022. There was no lease expense for the three and nine months ended September 30, 2021, as
the lease was part of the True Harvest Acquisition which was completed on December 31, 2021.
The Company operates a corporate office at 111
Broadway, Amityville, NY. The office is the Company’s registered office and headquarters. The office is paid for on a month-to-month
basis, with no restrictions upon exiting the property. As such, there are no commitments as part of the lease, and it is not included
in the table below.
Future minimum payments, to third parties, by
year and in the aggregate, consisted of the following as of September 30, 2022:
Remainder 2022 | |
$ | 319 | |
2023 | |
| 1,294 | |
2024 | |
| 1,332 | |
2025 | |
| 1,372 | |
2026 | |
| 1,414 | |
2027 | |
| 1,207 | |
| |
$ | 6,938 | |
11. Income Taxes
The Company is using the annual effective tax
rate for the nine months ended September 30, 2022. The annual effective tax rate may be subject to fluctuations during the year as new
information is obtained, which may affect the assumptions used to estimate the annual effective tax. rate for the three and nine months
ended September 30, 2022, the Company’s provision for income taxes were $948 thousand and $2,182 thousand, compared to $262 thousand
and $812 thousand, for the three and nine months ended September 30, 2021, respectively. The Company files income tax returns in the U.S.
federal jurisdiction and various state and local jurisdictions. The Company is subject to income tax examinations since inception by various
tax authorities.
Income taxes for the three and nine month periods
ending September 30, 2022 differs from the expected U.S. federal income tax rate of 21% of pre-tax earnings due to the impact of non-deductible
expenses and non-taxable income related to the change in fair value of warrants. The actual effective rate for the nine months ended September
30, 2022 was (3.71%.). The effective tax rate for the nine months ended September 30, 2022 differs from the U.S. statutory tax rate primarily
due to the impact of IRC Section 280E on Cannabis businesses. Under Section 280E of the Internal Revenue Code (IRC), no deduction or credit
is allowed for any amount paid or incurred during the taxable year in carrying on a business if the business consists of trafficking in
controlled substances (within the meaning of Schedules I and II of the Controlled Substances Act). The IRS has applied this provision
to cannabis operations, prohibiting them from deducting expenses associated with cannabis businesses.
In assessing the realization of the deferred tax
assets, management considers whether it is more likely than not that some portion of all of the deferred tax assets will not be realized.
The ultimate realization of deferred tax assets is dependent upon the generation of future taxable income during the periods in which
temporary differences representing net future deductible amounts become deductible. Management considers the scheduled reversal of deferred
tax liabilities, projected future taxable income and tax planning strategies in making this assessment. After consideration of all of
the information available, management believes that significant uncertainty exists with respect to future realization of deferred tax
assets and therefore established a full valuation allowance of $32 thousand as of September 30, 2022.
12. Financial Instruments
Private Warrant Liabilities
Prior to the Theraplant Business Combination,
Greenrose sold 1,980,000 private warrants to Greenrose Associates, LLC (the “Sponsor”) and Imperial Capital, LLC (“Imperial”).
Each private warrant is exercisable to purchase one share of common stock at an exercise price of $11.50 per share.
The private warrants are identical to the public
warrants as further described in Note 13, except that the private warrants will be exercisable for cash or on a cashless basis, at the
holder’s option, and be non-redeemable so long as they are held by the initial purchasers or their permitted transferees. If the
private warrants are held by someone other than the initial purchasers or their permitted transferees, the private warrants will be redeemable
by the Company and exercisable by such holders on the same basis as the public warrants.
The private warrants are measured at fair value
on a recurring basis. As of November 26, 2021 and December 31, 2021, the private warrants are classified as Level 2 due to the use of
an observable market quote in an active market.
The private warrants are accounted for as liabilities
in accordance with ASC 815-40 and are presented within the private warrant liabilities within the consolidated balance sheet. The private
warrants are measured at fair value at inception and on a recurring basis, with changes in fair value presented within change in fair
value of in financial instruments within the consolidated statements of operations.
The following table presents the changes in the
fair value of private warrants:
(in thousands) | |
Private Warrants | |
Fair value as of December 31, 2021 | |
$ | 436 | |
Value of private warrants issued | |
| 587 | |
Change in fair value | |
| (482 | ) |
Fair value as of June 30, 2022 | |
$ | 541 | |
Warrant Liabilities
As discussed in Note 8, in connection with the
Credit Agreement, on November 26, 2021, the Company entered into a warrant agreement (the “Warrant Agreement”) with the Lender
to issue 2,000,000 fully paid and nonassessable shares of the Company’s non-voting common stock. The Lender Warrants are immediately
exercisable and have an exercise price of $0.01 per warrant (i.e., penny warrants). The Lender can exercise the right to purchase the
common stock in part or in whole at any time or from time to time. The Lender Warrants will expire and no longer exercisable on November
25, 2026. The Lender is allowed to transfer or assign the rights of the Lender Warrants to any person or party as long as the transfer
would not violate U.S. federal or state securities law.
If current U.S. federal laws regarding cannabis
remain unchanged or the cultivation, manufacture, distribution, or possession of cannabis otherwise remains illegal under U.S. federal
law, then upon exercise of the warrant the Lender may elect to receive a cash amount equal to the fair value of such warrants (“Cash
Election”). In the case of the Cash Election, the Lender will not be able to exercise such election if the impact to the Company’s
capital would be insufficient to pay its obligations in the ordinary course of business. If liquidity concerns (insufficient capital to
pay its obligations in the ordinary course of business) do not allow the Company to settle the warrants in cash, then the Lender Warrants
will be paid in the form of a two-year secured promissory note.
On December 31, 2021, the Company amended the
Warrant Agreement (“Warrant Amendment”) by adding a price floor to the cash election feature whereas the Lender can elect
to net cash settle the warrants for an amount that is the greater of the fair market value of the Company’s share price or the price
floor. The price floor starts at $6.00 per share and increases $1.00 in each subsequent year on the initial term loan anniversary date.
Additionally, the expiration date of the warrants is now able to be extended by five successive one-year extensions if the sale of cannabis
continues to be federally illegal at the expiration date (the fifth anniversary of the issuance date and subject to five 1-year extensions
at the election of the holder).
In connection with the funding of the Delayed
Draw Term Loan, the Company issued another 550,000 warrants with identical terms as the initial 2,000,000 Lender Warrants as
amended by the Warrant Amendment for total Lender Warrants of 2,550,000. The Lender warrants were accounted for as liabilities in
accordance with ASC 815-40 and are presented within the warrant liabilities within the consolidated balance sheet. The Lender warrants
are measured at fair value at inception and on a recurring basis, with changes in fair value presented within change in fair value of
in financial instruments within the consolidated statements of operations. The change in fair value of these Lender Warrants were estimated
using the Monte Carlo simulation model.
On September 8, 2022, the Company received notices
of exercise from the holder of the lender warrants. The holder elected to exercise the warrants by making a cash election of the floor
amount of $6.00 per share. As the Company did not have sufficient capital to settle the warrants in cash, a two-year secured promissory
note was executed on October 12, 2022.
(in thousands) | |
Lender Warrants | |
Fair value as of December 31, 2021 | |
$ | 16,601 | |
Change in fair value | |
| 357 | |
Conversion to Note Payable | |
| (15,300 | ) |
Warrant Exercise - Receivable | |
| 25 | |
Gain on Exercise | |
| (1,683 | ) |
Fair value as of September 30, 2022 | |
$ | - | |
Derivative Liability
On October 20, 2021, in order to help facilitate
the closing of the Theraplant Business Combination, the Company and an investor (the “Investor”), entered into a Non-Redemption
Agreement (the “Non-Redemption Agreement”), pursuant to which the Investor agreed to purchase up to 1,000,000 shares
common stock of the Company, $0.0001 par value per share, in open market transactions or in private transactions from certain selling
shareholders who are not affiliated with the Company, at a purchase price not to exceed $10.14 per share.
In connection with the entry of the Non-Redemption
Agreement, Greenrose entered into a Registration Rights Agreement with the Investor (the “Registration Rights Agreement”)
pursuant to which Greenrose agrees to file a registration statement with the Securities and Exchange Commission (the “SEC”)
covering the resale of the Common Stock requested to be included in such registration statement (the “Resale Registration Statement”),
and Greenrose shall use its best efforts to have the Resale Registration Statement declared effective as soon as practicable after the
filing thereof, but in no event later than the 45th calendar day following the filing of the Resale Registration Statement (or, the fifth
calendar day following the date on which the Company is notified by the SEC that the Resale Registration Statement will not be or is no
longer subject to further review and comments.
Further, as part of the Non-Redemption Agreement,
Greenrose and the Investor have agreed that Greenrose shall issue and sell to the Investor, and the Investor shall purchase from Greenrose,
for the sum of $500, an aggregate of 500,000 newly issued shares of Greenrose Common Stock (“Investor Shares”). When
issued, these shares are to be subject to a lock-up and will be released based on a contractual calculation each month for six months.
Any shares not released within that six-month period shall be forfeited. During the period ended December 31, 2021, the Company released
141,000 shares from lock-up, and as of September 30, 2022 the remaining 359,053 shares were released from lock-up (“Released
Shares”).
13. Stockholders’ Equity/Members’ Equity
Common Stock - The Company is authorized
to issue up to 150,000,000 shares of common stock with a par value of $0.0001 per share. Holders of the common stock are entitled
to one vote for each share. After consideration redemptions of common stock, there were 6,630,000 shares issued and outstanding on
the date of the Theraplant Business Combination and 5,000,000 shares issued on November 26, 2021, to consummate the Theraplant Business
Combination for a total of 11,630,000 shares of common stock issued and outstanding. The Company issued an additional 4,430,000
shares on December 31, 2021 in connection with the True Harvest acquisition and had total shares of common stock outstanding of 16,061,000 as of December 31, 2021.
On February 18, 2022, the Company granted 57,000
stock options, all of which are vested and have a 5-year term. The options have a strike price of $5.25. The Company also issued 74,000
fully vested shares of common stock as stock-based compensation at $5.25 a share.
On March 14, 2022, the Company issued an aggregate
of 753,165 unregistered shares common stock to YA II PN, Ltd. 500,000 shares were issued in connection with the October 21, 2021 execution
of a Non-Redemption Agreement and 253,165 shares were issued to settle $1,000 thousand of accrued expenses related to a Standby Equity
Purchase Agreement (collectively, the “YA II PN, Ltd Agreements”). The Company previously disclosed the execution of the YA
II PN, Ltd Agreements on the Form 8-K filed with the US Securities and Exchange Commission on October 21, 2021.
On March 15, 2022, the Company issued an aggregate
of 73,700 unregistered common shares to certain board members as consideration for services performed as members of the board of directors.
On March 16, 2022, the Company issued an aggregate
of 11,905 unregistered common shares to Acorn Management Partners, LLC (“Acorn”) in exchange for marketing services. This
agreement requires an issuance of $50 thousand worth of stock and $10 thousand per month for a period of six months with the ability to
extend for three month periods an additional $25 thousand of restricted stock and $10 thousand per month.
On June 7, 2022, the Company issued an aggregate
of 64,312 unregistered common shares to Imperial as a retainer payment on the Imperial Note. The shares issued were worth $250 thousand
as determined by the five consecutive trading day volumed weighted average price of the Company’s common stock as of the date of
execution of the engagement letter with Imperial.
On July 7, 2022, the Company issued an additional
33,783 unregistered common shares to Imperial that were worth $75 thousand. The Company is required to issue $75 thousand worth of stock
for each of the next two quarters, and $150 thousand worth of stock each subsequent quarter through maturity of the note in accordance
with the agreement with Imperial.
On August 8, 2022, the Company granted 176,000
stock options, all of which are vested and have a 15-year term. The options have a strike price of $2.38.
On August 29, 2022, the Company granted 50,000
stock options, all of which are vested and have a 5-year term. The options have a strike price of $1.75.
Preferred Stock - The Company is authorized
to issue up to 1,000,000 shares of preferred stock with a par value of $0.0001 per share with such designation, rights and preferences
as may be determined from time to time by the Company’s board of directors. No shares of preferred stock are issued or outstanding.
Warrants - Pursuant to the initial public
offering, the Company sold 17,250,000 Units, at a price of $10.00 per Unit. Each Unit consisted of one share of common stock and
one warrant (“public warrant”). Each public warrant entitles the holder to purchase one share of common stock at a price of
$11.50 per share, subject to adjustment. The public warrants will become exercisable on the later of (a) 30 days after the completion
of a Business Combination or (b) 12 months from the closing of the Initial Public Offering. No warrants will be exercisable for cash unless
the Company has an effective and current registration statement covering the shares of common stock issuable upon exercise of the warrants
and a current prospectus relating to such shares of common stock. Notwithstanding the foregoing, if a registration statement covering
the shares of common stock issuable upon exercise of the public warrants is not effective within a specified period following the consummation
of a Business Combination, warrant holders may, until such time as there is an effective registration statement and during any period
when the Company shall have failed to maintain an effective registration statement, exercise warrants on a cashless basis pursuant to
the exemption provided by Section 3(a)(9) of the Securities Act, provided that such exemption is available. If that exemption, or another
exemption, is not available, holders will not be able to exercise their warrants on a cashless basis. The public Warrants will expire
five years after the completion of a Business Combination.
The Company may redeem the public warrants:
|
● |
in whole and not in part; |
|
● |
at a price of $0.01 per warrant; |
|
● |
upon not less than 30 days’ prior written notice of redemption; |
|
● |
if, and only if, the reported last sale price of the Company’s common stock equals or exceeds $18.00 per share for any 20 trading days within a 30-trading day period ending on the third business day prior to the notice of redemption to the warrant holders; and |
|
● |
if, and only if, there is a current registration statement in effect with respect to the shares of common stock underlying the warrants. |
If the Company calls the Public Warrants for redemption,
management will have the option to require all holders that wish to exercise the public warrants to do so on a “cashless basis,”
as described in the warrant agreement.
The exercise price and number of shares of common
stock issuable upon exercise of the warrants may be adjusted in certain circumstances including in the event of a stock dividend, or recapitalization,
reorganization, merger, or consolidation. However, the warrants will not be adjusted for issuance of common stock at a price below its
exercise price. Additionally, in no event will the Company be required to net cash to settle the warrants. If the Company is unable to
complete a Business Combination within the Combination Period and the Company liquidates the funds held in the Trust Account, holders
of warrants will not receive any of such funds with respect to their warrants, nor will they receive any distribution from the Company’s
assets held outside of the Trust Account with the respect to such warrants. Accordingly, the warrants may expire worthless.
In addition, if (x) the Company issues additional
shares of common stock or equity-linked securities for capital raising purposes in connection with the closing of an initial Business
Combination at an issue price or effective issue price of less than $9.50 per share of common stock (with such issue price or effective
issue price to be determined in good faith by the Company’s board of directors, and in the case of any such issuance to the Sponsor,
initial stockholders or their affiliates, without taking into account any Founder Shares held by them prior to such issuance), (y) the
aggregate gross proceeds from such issuances represent more than 60% of the total equity proceeds, and interest thereon, available for
the funding of an initial Business Combination on the date of the consummation of an initial Business Combination (net of redemptions),
and (z) the volume weighted average trading price of the common stock during the 20-trading day period starting on the trading day prior
to the day on which the Company consummates an initial Business Combination (such price, the “Market Value”) is below $9.50
per share, the exercise price of the warrants will be adjusted (to the nearest cent) to be equal to 115% of the greater of (i) the Market
Value or (ii) the price at which the Company issues the additional shares of common stock or equity-linked securities.
The following is a list of the outstanding warrants
as of September 30, 2022:
(in thousands) Instrument | |
Number of Warrants Outstanding | | |
Classification |
Public Warrants | |
| 17,250 | | |
Equity |
Private Warrants | |
| 3,873 | | |
Liability |
Lender Warrants | |
| - | | |
Liability |
Total | |
| 21,123 | | |
|
Standby Equity Purchase Agreement
On October 20, 2021, Greenrose and the Investor,
entered into a Standby Equity Purchase Agreement (the “Equity Purchase Agreement”), whereby the Investor agreed to purchase
from the Company up to $100,000 thousand of the Company’s shares of common stock, par value $0.0001 per share (the “Common
Stock”), for a purchase price per share of 96% multiplied by the lowest daily volume weighted average price of shares during regular
trading hours as reported by Bloomberg L.P. of the Company’s common stock during the three (3) consecutive trading days commencing
on the advance notice date. As a commitment fee, the Company incurred $1,000 thousand to establish the Equity Purchase Agreement and such
fees remain unpaid as of year-end and have been included in accrued expenses. Additionally, the Company concluded these fees are direct
and incremental fees to a future offering of equity securities and as such, the Company has deferred the $1,000 thousand to be offset
against future equity offering proceeds. The deferred costs are included within Other Assets on the consolidated balance sheet as of September
30, 2022 and December 31, 2021, as no such equity offering has been made. The deferred costs will be offset to equity when purchases are
made on the Equity Purchase Agreement.
Predecessor Period
The Predecessor’s operating agreement provided
for the issuance of Series A Units, Angel Founder Units, Series R Units and Service Units.
The Series A Units, Angel Founder Units and Series
R Units had voting rights, whereas the Service Units are non-voting.
The operating agreement allowed for managing members
to make periodic distributions to members in connection with taxable income allocated to members for income tax purposes multiplied by
the assumed income tax rate of 44% (“Tax Distributions”). Other distributions, as approved by managing members, are based
on each members’ unit percentage interest. Distributions to Angel founder members were subordinated to a return of the Series A
members’ value of their capital interests at the time of the issuance of the Series R Units. The Series A preferred members had
a preference on distributions (“Preferred Distributions”) totaling 90% of any distributions until they received their initial
investment plus an additional 35%. Only Angel Founder members were entitled to the 10% distribution until the Series A members were paid
off. Once the Series A members have received their initial investment plus the 35%, all distributions going forward are paid pro-rata
amongst all units.
The Predecessor issued 110,000 Angel Founder Units,
and 42,761 Series A Units during 2013. On September 17, 2018, the Company issued 54,000 Series R Warrants. On January 7, 2020, 29,000
Series R Warrants were exercised, and on March 12, 2020, the remaining 25,000 Series R Warrants were exercised, resulting in 54,000 Series
R Units being issued in exchange for the warrants. As of December 31, 2020, the Predecessor had issued 110,000 of Angel Founder Units,
54,000 of Series R Units, and 42,761 of Series A Units. Each of these Units has equal ownership of the Predecessor and recorded income
and distributions pro rata once all shares were issued and vested.
Except for Tax Distributions and Preferred Distributions
as discussed above, distributions made to Members in proportion to their respective Percentage Interests as of the time of such distribution.
All Service Units were intended to constitute
profit interests for U.S. federal income tax purposes. No Service Units were issued.
On September 17, 2018, the Predecessor issued
54,000 warrants to various members of management. The warrants vested immediately and had an exercise price of $1 per unit. During the
first quarter of 2020, the warrant holders exercised their options resulting in the Company issuing 54,000 Series R Units to the warrant
holders.
14. Stock-Based Compensation
The Company sponsors an equity incentive plan
(the “Plan”) in which certain employees and non-employee directors participate. The Plan is administered by the compensation
committee of the board of directors of the Company (the “Compensation Committee”). The Company measures the cost of services
received in exchange for an award of equity instruments (typically restricted stock unit awards (“RSUs”) and stock options)
based on the grant-date fair value of the awards issued under the Plan that are equity classified. Liability classified RSUs are valued
based on the fair value of the stock at each reporting period until the date of settlement with changes in fair value recognized as increases
or decreases in stock-based compensation expense in the accompanying consolidated statements of comprehensive income (loss) each reporting
period over the period during which an employee or non-employee director is required to provide service in exchange for the awards, usually
the vesting period. The fair value of the stock options is calculated using the Black-Scholes option-pricing model. Forfeitures are accounted
for as they occur.
The fair value of each option award is estimated
on the date of the grant, using the Black-Scholes option-pricing model and the assumptions in the following table:
On February 18, 2022, the Company granted 57,000
stock options, all of which are vested and have a 5-year term. The options have a strike price of $5.25. The Company also issued 74,000
fully vested shares of common stock as stock-based compensation at $5.25 a share.
On August 8, 2022, the Company granted 176,000
stock options, of which 25% vested on the effective date and the remaining 75% have a 2-year vesting period. The options have a 15-year
term and have a strike price of $2.38.
On August 29, 2022, the Company granted 50,000
stock options, all of which are vested and have a 5-year term. The options have a strike price of $1.75.
The following table is a summary of stock-based
compensation expense for the periods:
Basic earnings per share is based on the weighted
average number of shares of common stock issued and outstanding during the period. Diluted earnings per share is based on the weighted
average number of shares of common stock issued and outstanding and the effect of all dilutive common stock equivalents and potentially
dilutive securities outstanding during the period. The potentially dilutive securities that would be anti-dilutive due to the Company’s
net loss are not included in the calculation of diluted net loss per share.
The following table reconciles the numerators
and denominators used in the computations of both basic and diluted earnings per share for the Successor Period:
The Company has also considered the dilutive impact
of the public and private warrants, True Harvest convertible debt, contingent consideration payable in shares to the True Harvest sellers,
True Harvest contingently returnable shares, Sponsor Notes, and the Deferred Cash Payment convertible into shares, Investor Shares, stock
options, Lender Warrants, and shares issuable under share-settled debt arrangements each of which was determined to be anti-dilutive.
The following table reconciles the numerators
and denominators used in the computations of both basic and diluted earnings per share for the Predecessor Periods. There were no securities
that were determined to be dilutive.
In order to finance transaction costs in connection
with a Business Combination, the Sponsor, or certain of the Company’s officers and directors or their affiliates have loaned the
Company funds that were required to complete the initial Business Combination.
On March 26, 2020 (Prior to the Theraplant Business
Combination), the Company issued an unsecured promissory note (the “2020 Note”) in the principal amount of $1,000 thousand
to the Sponsor and on January 29, 2021 (Predecessor), the Company issued an additional unsecured promissory note (the “2021 Note”)
in the principal amount of $1,000 thousand to the Sponsor. The 2020 and 2021 Notes are non-interest bearing and payable upon the consummation
of a Business Combination. The full amount of such loans may be convertible into units at a price of $10.00 per unit and/or warrants at
a price of $1.00 per warrant.
In addition to the 2020 and 2021 Notes, on June
18; August 26; September 9; September 20; October 1; and November 1, 2021, the Company issued unsecured promissory notes, in the principal
amount of $300 thousand, $450 thousand, $180 thousand, $65 thousand, $100 thousand, and $140 thousand, respectively, to the Sponsor evidencing
loans in the same amount for a total of $1,235 thousand (the “Promissory Notes” and collectively with the 2020 Note and 2021
Note, the “Sponsor Notes”). The Promissory Notes are non-interest bearing and payable upon the consummation of a Business
Combination. During 2021, $595 thousand of cash was paid out of the Company’s operating cash account to fund extensions of the Company
to complete the Theraplant Business Combination. These payments were made on behalf of the Sponsor and have therefore reduced the aggregate
principal owed to the Sponsors by the same amount.
On November 26, 2021, in connection with the execution
of the Term Loan as discussed in Note 8, the Company agreed that none of the Sponsor Notes would be settled in cash.
On January 31, 2022, the Greenrose board of directors
and the Lender have approved the final settlement amount of the Sponsor Notes. The aggregate principal amount outstanding on the date
of settlement was $2,640 thousand and was settled for 685,000 shares of Greenrose common stock and 1,893,000 private warrants
which was determined to approximate the principal amount outstanding.
On February 2, 2022, Greenrose entered into an
exchange agreement (the “Exchange Agreement”) with Greenrose Associates LLC, the Company’s sponsor to convert $2,640
thousand in aggregate principal amount of promissory notes and convertible notes into (i) 685,000 shares of common stock of the Company,
par value of $0.0001 per share, and (ii) 1,893,000 non-callable private warrants entitling the holder thereof to purchase one share
of Common Stock at $11.50 per share for five (5) years from the date of issuance. The Sponsor Notes were non-interest bearing and did
not contain a stated maturity date. The non-callable private warrants contained the same terms and conditions as the private warrants
issued to the Company’s Sponsor and the Company’s underwriters in connection with its February 11, 2020 initial public offering.
Simultaneously with the entry of the Exchange
Agreement, Greenrose issued all 685,000 shares of common stock of the Company to the Sponsor in a private placement exempt from registration
pursuant to Rule 506(b) of Regulation D under Section 4(a)(2) of the Securities Act of 1933, as amended. Upon the issuance of the 685,000 shares of common stock and 1,893,000 warrants of the Company, the Sponsor Notes were cancelled and are no longer outstanding.
The terms and conditions of the conversion of
the Sponsor Notes into shares of common stock and Private Warrants of the Company, including the conversion price, were approved at a
meeting of a special committee of the independent members of the board of directors of the Company, in which members of the board of directors
who were also members of the Sponsor were recused.
The Company assessed the provisions of the 2020
and 2021 Notes under ASC 815-15 and initially determined the conversion feature to be a derivative liability that required bifurcation
from the host instrument. The conversion feature was initially valued and classified as a derivative liability with an offset to a discount
on the 2020 and 2021 Notes.
The discount was amortized over the expected life
of the 2020 and 2021 Notes and was fully amortized through interest expense within the Company’s historical statement of operations
prior to the Theraplant Business Combination. To calculate the value of the embedded derivative the Company utilized a “with”
and “without” approach. In the “with” scenario we valued the convertible promissory notes using a Black-Scholes
model as it was determined that on a business combination, a holder would likely convert into private warrants, which were themselves
valued using a Black-Scholes model and are considered to be a Level 3 fair value Measurement (see Note 9). In the “without”
scenario, the Company valued the repayment of the notional value of the convertible promissory note using a risk-adjusted discounted cash
flow model. The 2020 and 2021 Notes had reached maturity with both of the conversion scenarios out of the money and the final settlement
would subsequently be adjusted to settled in an agreed upon value within equity or private warrants. As such, the Company has concluded
the bifurcated derivative liability had no value as of November 26, 2021 and December 31, 2021 and the final settlement would approximate
the 2020 and 2021 carrying amount.
Management has evaluated subsequent events to
determine if events or transactions occurring through the filing date of this Quarterly Report on Form 10-Q require adjustment to or disclosure
in the Company’s Financial Statements.
In October, the company did not make its quarterly
interest payment to its Lender.
Related to the above, on October 10, 2022 the
Company received a notice of additional default (the “Notice of Additional Default”) from the legal representatives on behalf
of DXR Finance, LLC (“DXR Finance”), in reference to the Credit Agreement, by and among the Company, as Borrower.
As previously reported with the filing of the
8-K report on October 4, 2022, the Company received a notice of default (the “Notice of Default”) from the legal representatives
on behalf secured lender on October 2, 2022. The secured lender notified the Company that it is considering its rights and remedies pursuant
to the loan agreement, and without waiving any rights, remedies, powers, privileges and defenses afforded under the loan.
On October 3, 2022, the board of directors of
the Company adopted amended and restated bylaws. The bylaws amendment introduces a process and procedures and imposes certain information
requirements on the Company’s stockholders when one or more stockholders seek to call a special meeting of the stockholders or take
action by written consent, thereby ensuring these stockholder actions are effected in a lawful, valid and transparent manner by then-holders
of the Company’s voting stock.
As previously reported with the filing of the
8-K report on October 13, 2022, on October 12, 2022, the Company, together with its wholly-owned subsidiaries Theraplant, LLC and True
Harvest Holdings, Inc. as Guarantors, entered into the Forbearance Agreement with the Lenders party to the Credit Agreement and DXR Finance,
LLC as Agent (the “Forbearance Agreement”). Pursuant to the Forbearance Agreement the parties thereto have agreed that that
the Lenders and the Agent shall provide a limited forbearance (as set forth in Section 2.02 of the Forbearance Agreement) by terms of
which the Lenders and the Agent shall forbear from accelerating the Obligations and otherwise exercising any rights, remedies, powers,
privileges and defenses under the Credit Agreement and the other Loan Documents (as defined in the Credit Agreement), for the Forbearance
Period (as defined in the Section 2.02 of the Forbearance Agreement) that shall expire on the Forbearance Termination Date (as defined
in the Forbearance Agreement) and subject to the terms and conditions thereof, solely as a result of the existence of the Specified Defaults
listed in the Forbearance Agreement.
Simultaneously with entering into the
Forbearance Agreement, the Company entered into a secured promissory note in the principal amount of U.S.$15,300 thousand with DXR
Finance, LLC as the Agent for the benefit of the Lenders under the Forbearance Agreement (the “Promissory Note”),
pursuant to the terms of the Closing Date Warrant and the Delayed Draw Warrant (as defined in the Credit Agreement), as amended,
restated, amended and restated, supplemented and otherwise modified from time to time prior to the date of the Promissory Note. On
each Interest Payment Date (as defined in the Credit Agreement), the Company shall pay to the Agent U.S.$1,913 thousand of the
principal amount of the loan. Subject to the acceleration provisions of Section 6 of the Promissory Note, any unpaid principal, fees
and accrued and unpaid interest and all other amounts shall be due and payable in full on the date that is two (2) years from the
date of the Promissory Note (the “Maturity Date”). The unpaid principal amount of the Promissory Note shall accrue
interest daily on the basis of a 360 day year at the LIBO Rate plus sixteen per cent (16.00%) per annum, provided that upon the
occurrence and during the continuance of an Event of Default (as defined in the Forbearance Agreement), the outstanding principal
amount of this Note and any accrued and unpaid interest and all other overdue amounts shall each bear interest until paid at the
stated rate plus two per cent (2.00%) per annum. Interest shall be due and payable in arrears on each Interest Payment Date (as
defined in the Credit Agreement). After the Maturity Date (as defined in the Promissory Note and referenced above), interest will
continue to accrue on any unpaid principal and shall be due and payable on demand. The LIBO Rate shall not at any time be less than
one per cent (1.00%) per annum. The Company may at any time and from time to time prepay any principal amount on the Promissory Note
in whole or in part without premium or penalty. Payments and prepayments made by the Company shall be applied first to expenses
recoverable under the Promissory Note, then to accrued and unpaid interest and lastly to principal.
On October 9, 2022, in accordance with the bylaws
of the Company and Delaware law, the Board of Directors of the Company (the “Board”) expanded the number of directors on the
Board from seven (7) to nine (9) and appointed two (2) new directors, Messrs. Jarom Fawson and Tom Lynch to serve on the Board. Simultaneously,
the Board also appointed Messrs. Fawson and Lynch to the Special Committee.
As previously reported with the filing of the
8-K report on October 20, 2022, on October 18, 2022, the Company, its Board of Directors and Special
Committee, on October 18, 2022, Ducera Securities LLC was engaged, to provide certain financial advisory and investment banking
services, if requested, and advice on potential restructuring, sale, and/or other strategic transactions.
On each of October 19, 2022, October 27, 2022
and November 3, 2022 the Company and the other parties to the Forbearance Agreement agreed to extend by one week the Forbearance Period
while the Company was actively working with the Lenders under the Credit Agreement (including certain of our related parties) towards
a solution or a group of solutions.
As reported with the filing of the 8-K report
on November 14, 2022, on November 10, 2022, the Company, together with its wholly-owned subsidiaries, Theraplant LLC and True Harvest
Holdings, Inc., entered into the Transaction Support Agreement with the Note Holders (as defined below) and the Lenders (the “Credit
Agreement Consenting Lenders”, and collectively with the Note Holders, the “Consenting Lenders”) party to that certain
Credit Agreement dated November 26, 2021 (as amended by that certain Amendment No. 1 to Credit Agreement, dated as of December 31, 2021,
and as further amended by Amendment No. 2 to Credit Agreement (as defined below), the “Credit Agreement”) and DXR Finance,
LLC (the “Agent”), in its capacity as Agent under the Credit Agreement (the “Transaction Support Agreement”).
The Transaction Support Agreement contemplates
that the Company will pursue either a Qualified Alternative Transaction Proposal (as defined below) or a consensual Foreclosure (as defined
below), in each case as described in more detail below. To the extent the Greenrose Entities pursue the Foreclosure, the Foreclosure will provide for, among other things: (i) the continuation
of the Theraplant and True Harvest businesses as a going concern; (ii) the assumption of employee liabilities, accounts payable and liabilities
under assumed contracts; and (iii) NewCo (as defined below) will be obligated to offer each employee of Theraplant and TH employment at
NewCo at (but subject to) closing of the Foreclosure on substantially the same terms as such employees’ existing employment arrangements.
For up to 50 days following entry into the
Transaction Support Agreement, with the assistance of their advisors, including Ducera Securities LLC, the Company will use
commercially reasonable efforts to market themselves and their assets with the goal of receiving binding transaction proposals for,
including but not limited to, a sale, disposition, reorganization, merger, financing or other type of transaction that, among other
conditions, satisfies the payment obligations owed by the Company under the Credit Agreement, the DXR Secured Promissory Note (as
defined below) and related loan documents (the “Obligations”), or is on such other terms as are acceptable to the
Company, the Consenting Lenders and the Agent (such a proposal, a “Qualifying Alternative Transaction Proposal”). If the
Company have not received an alternative transaction proposal that reasonably could become a binding Qualifying Alternative
Transaction Proposal by not later than 30 days following the entry into the Transaction Support Agreement, then the marketing period
shall end and the Company’s obligations under the Transaction Support Agreement with respect to the Foreclosure shall commence
from and after the date upon which the Consenting Lenders deliver the Foreclosure Agreement. In the event that the Company receive
more than one Qualifying Alternative Transaction Proposal, the Company shall hold an auction to determine the winning proposal.
On November 10, 2022, concurrently with the execution
of the Transaction Support Agreement, Company, as Guarantors, entered into an Amendment No. 2 to the Credit Agreement with the Credit
Agreement Consenting Lenders and DXR Finance, LLC, as Agent (“Amendment No. 2 to the Credit Agreement”) pursuant to which
the Credit Agreement Consenting Lenders agreed to fund an additional $10,000 thousand of loans, with $5,000 thousand to be borrowed immediately
on the effective date of the Amendment No. 2 to the Credit Agreement and $5,000 thousand to be borrowed in one or more draws thereafter on
or before December 31, 2022. Amendment No. 2 to the Credit Agreement also provided for certain amendments to the Credit Agreement to facilitate
the transactions contemplated by the Transaction Support Agreement. In addition, as consideration for the Credit Agreement Lenders’ entry into Amendment No. 2 to Credit Agreement, the make whole period
applicable to the loans under the Credit Agreement was extended by three (3) months to the thirty third month anniversary of the original
closing date of the Credit Agreement.
If the Company fail to enter into a binding, fully
executed Qualifying Alternative Transaction Proposal within the time periods specified in the Transaction Support Agreement, the Consenting
Lenders and Agent will effectuate a foreclosure through the formation of a newly-formed company (“NewCo”) that will transmit
an offer, in the form of a foreclosure agreement (the “Foreclosure Agreement”), to the Company to accept the Agent’s
collateral (which constitutes substantially all assets of the Company and its wholly owned subsidiaries, Theraplant, LLC and True Harvest
Holdings, Inc.) (the “Foreclosure”). Upon consummation of the Foreclosure, NewCo will also (i) assume certain liabilities
of the Company, including employee liabilities, accounts payable and liabilities under assumed contracts and (ii) agree to fund the Company’s
anticipated tax liabilities (collectively, the “NewCo Liabilities”). The consummation of the Foreclosure is subject to conditions
set forth in the Transaction Support Agreement, including the provision by the Consenting Lenders of sufficient wind-down funding, receipt
of required regulatory approvals and the execution of a mutual release agreement between the Company, on the one hand, and NewCo, the
Agent and Consenting Lenders, on the other hand, and new indemnification agreements between NewCo and current officers and directors of
the Company.
The Transaction Support Agreement may be automatically
terminated upon the occurrence of specified events, including, without limitation, the consummation of the Foreclosure, any material breach
of the Transaction Support Agreement that is not cured within ten days of receipt of written notice, or the date that is 90 days from
the date on which the Company present the Transaction Support Agreement to the Connecticut Department of Consumer Protection. For a period of 25 days after the entry into the Transaction Support Agreement (the “Limited Diligence
Out Period”), the Agent and Consenting Lenders may also terminate the Transaction Support Agreement to the extent that the Company
(i) breach their obligation to make certain information available to the Agent and Consenting Lenders in connection with their diligence
review of the NewCo Liabilities and fail to cure such breach within either five days’ notice of such breach or by the expiration
of the Limited Diligence Out Period or (ii) the Agent or Consenting Lenders discover material NewCo Liabilities which were not previously
disclosed by the Company.
On November 10, 2022, concurrently with the execution of the Transaction
Support Agreement, the Company, as Guarantors, entered into a forbearance agreement with the Lenders party to the Credit Agreement, the
holders (the “Note Holders”) of that certain Secured Promissory Note in an original principal amount of $15,300 thousand dated
as of October 12, 2022 (the “DXR Secured Promissory Note”) and DXR Finance, LLC, as Agent (the “Forbearance Agreement”).
Pursuant to the Forbearance Agreement the parties thereto agreed that that the Lenders, the Note Holders and the Agent will provide a
limited forbearance (as set forth in Section 2.02 of the Forbearance Agreement) by terms of which the Lenders and the Agent will forbear
from accelerating the Obligations and otherwise exercising any rights, remedies, powers, privileges and defenses under the Credit Agreement,
the DXR Secured Promissory Note and related loan documents as a result of the existence of certain types of Events of Default, for the
Forbearance Period (as defined in the Forbearance Agreement) that will expire on the Forbearance Termination Date (as defined in the Forbearance
Agreement).
In connection with the Transaction Support Agreement,
the Company paid to the Agent for the benefit of the Credit Agreement Lenders party to the Forbearance Agreement a forbearance payment
equal to 1.00% of the principal amount of loans outstanding under the Credit Agreement immediately prior to the effectiveness of the Forbearance
Agreement, and will pay (subject to the occurrence of certain events as more fully described in the Forbearance Agreement) such additional
forbearance payments as provided in the Forbearance Agreement.
The foregoing descriptions of the Transaction
Support Agreement, Amendment No. 2 to the Credit Agreement and the Forbearance Agreement do not purport to be complete and are subject
to and qualified in their entirety by reference to the complete text of agreements, copies of which are filed as Exhibits 10.1, 10.2 and
10.3 to the Current Report on Form 8-K filed on November 14, 2022, and are incorporated herein by reference.
Although the Company intends to pursue the transactions
described herein in accordance with the terms and conditions set forth in the Transaction Support Agreement, there can be no assurance
that the Company will be successful in consummating transactions on the terms and conditions set forth in the Transaction Support Agreement.